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bind up to six hemes tightly across a membrane interface. Chapter four demonstrates that AP6 successfully
performs quinol-cytochrome c oxidoreductase activity in hundreds of milliseconds. AP6 is the first example
of a synthetic enzyme capable of near-natural turnover rates. Chapter five focuses on defining the
thermodynamic limit for maquette activity. This work supports the further development of simple model
proteins to study aspects of Complex III mechanism.
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ABSTRACT 
 
 
DECONVOLUTING THE ENGINEERING AND ASSEMBLY 
 INSTRUCTIONS FOR COMPLEX III ACTIVITY  
 
Sarah Chobot Hokanson 
 
 
 
P. Leslie Dutton, Ph.D., FRS 
 
 
 In respiratory systems, membrane-bound Complex III catalyzes the oxidation of 
ubiquinone and the reduction of a soluble cytochrome with the bioenergetic formation of 
a transmembrane proton gradient (∆µH+).  Complex III turnover is initiated by a unique 
two electron oxidation of ubiquinone at the Qo site; one electron is delivered to a high 
potential chain containing an iron-sulfur cluster, cytochrome c1 and cytochrome c2, and a 
second electron is transferred to a low potential chain that terminates at the Qi site.  All 
Complex III electron tunneling reactions are reversible, and a critical part of Complex III 
maintaining productive turnover is its suppression of energy-wasting reverse electron 
transfer reactions.  The key to uncovering the controversial mechanism of Qo oxidation is 
determining how Complex III is regulated such that productive electron-transfer steps 
overwhelm unproductive steps.   
 This thesis focuses on understanding the structural and biochemical tolerances of 
the redox cofactors in Complex III and applying that knowledge towards the design of a 
simple, but robust, amphiphilic maquette that is capable of transmembrane proton and 
electron transfer. In chapter two, kinetic studies of heme c1 mutants reveal that R. 
sphaeroides Complex III is engineered to withstand large changes in heme c1 active site 
residues while still preserving heme c1 midpoint potential and enzyme turnover.  In 
	   ix	  
chapter three, the maquette approach was applied toward developing a simple model 
protein (AP6) that retained the minimum engineering requirements for Complex III 
electron and proton transfer reactions but lacked the complexity found in the natural 
system.  The AP6 peptide assembles as a four-α-­‐helix bundle protein and can potentially 
bind up to six hemes tightly across a membrane interface. Chapter four demonstrates that 
AP6 successfully performs quinol-cytochrome c oxidoreductase activity in hundreds of 
milliseconds.  AP6 is the first example of a synthetic enzyme capable of near-natural 
turnover rates.  Chapter five focuses on defining the thermodynamic limit for maquette 
activity.  This work supports the further development of simple model proteins to study 
aspects of Complex III mechanism.   
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Chapter 1:  Introduction 
 
 
 
 
 
 
 
 
 
Thirty years ago, Peter Mitchell won the Nobel Prize for the development of the Q-cycle 
model that advanced our understanding of Complex III.  While the principle tenets of his 
Q-cycle still hold true today, Mitchell did not explain the specific mechanism that allows 
the Qo site to perform this Q-cycle efficiently without undue energy loss.  Though much 
speculation on Qo site mode of molecular action and regulation has been introduced over 
the thirty years after Mitchell collected his Prize, no single mechanism has been 
universally accepted.  In this introductory chapter, the history behind the search for the 
true Qo mechanism is discussed, and the current models for the mechanism of Complex 
III electron tunneling reactions are examined.  Portions of this chapter have been included 
in the following references [1, 3, 4] and are reprinted with permission from SpringerLink, 
the Journal of Bioenergetics and Biomembranes [3, 4], and Biochimica et Biophysica 
Acta – Bioenergetics [1].   
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1.1 A summary of mitochondrial respiration 
We now mostly understand the basic electron tunneling reactions (Figure 1.1 blue 
arrows) that connect the complexes within the mitochondrial respiratory chain together.  
In Complexes I and II, flavin-containing nicotinamide adenine dinucleotide (NADH) and 
succinate dehydrogenase sites are connected via ubiquinone sites in the membrane 
domain.  These sites collect single electrons of the tunneling chains into pairs for two 
electron and two proton quinone oxidation-reduction before exchanging with a 
membranous quinone pool.  Complex III interacts with the quinone pool via two 
ubiquinone oxidation-reduction sites, Qo and Qi, Once reduced Qo is bound to Complex 
	  	  
Figure 1.1: A contemporary view of the mitochondrial respiratory chain, which 
contains (left to right) Complex I, Complex II, Complex III, cytochrome c, and 
Complex IV.  Blue arrows indicate electron tunneling pathways, red arrows indicate 
the direction of proton translocation, black arrows indicate the arrival/placement of 
substrate molecules, and green arrows indicate the position and movement of quinone 
molecules.   This figure was modified from a figure presented in Biochimica et 
Biophysica Acta – Bioenergetics [1]. 	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III, one electron reduces cytochrome c1 while the other electron equivalent passes through 
two b-type hemes and reduces a quinone molecule at the Qi site.  In the terminal 
Complex IV, cytochrome c electron transfer leads to dioxygen reduction. 
 Although the overall stoichiometries of redox-linked proton exchange (red 
arrows, Figure 1.1) are known, the basics these are coupled to the electron tunneling 
reactions of ubiquinone (Complexes I, II and III) or dioxygen (Complex IV) that generate 
the transmembrane electrochemical proton gradient (ΔµH+) remain undefined and 
controversial.  The most information is known about Complex IV, as the key 
intermediate redox states of the stepwise four-electron reduction of dioxygen have been 
resolved structurally [7, 8] and spectroscopically [9-11].  However, the molecular 
mechanism of its driven proton pump remains to be determined. Information about the 
operation of the Qs site in Complex II is limited [12]; most experiments have been 
focused on the redox chemistry of its FeS clusters [13, 14] and heme b [15-17] instead.  
Incomplete structural information available for Complex I has limited the resolution of its 
proton pumping mechanism, though several hypotheses exist in the literature at present 
[18-23].  One of the most controversial questions left unanswered about the operation of 
the mitochondrial respiratory chain is the molecular mechanism of ubiquinone oxidation-
reduction, proton exchange and energy coupling at the Qo site in Complex III.  In sharp 
contrast to Complex IV, the redox intermediate states of Qo have proven difficult to 
access, lack clear spectroscopic signatures, and remain highly uncertain.  
1.2 Redox cofactors in the mitochondrial respiratory chain 
Energy obtained by electron transfer through the mitochondrial respiratory chain 
is also used to pump protons from the mitochondrial matrix into the intermembrane 
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space, creating an electrochemical proton gradient across the mitochondrial inner 
membrane (ΔµH+).  This electrochemical proton gradient allows adenosine triphosphate 
(ATP) synthase to use the flow of protons to generate ATP from adenosine diphosphate 
(ADP) and inorganic phosphate. In the absence of ADP, protons cannot flow back to the 
matrix, and the pH and electrical gradients are at maximum. As respiration with outward 
proton pumping proceeds, the free energy change for proton expulsion increases and 
approaches the magnitude of that for electron transfer.  When the coupled reaction 
becomes non-spontaneous, respiration stops, and this state is called a static head.  The 
formation of reactive oxygen species is supported by static head conditions in the 
mitochondrial respiratory chain [24]. 
 There are many different types of redox-active cofactors responsible for proton-
coupled electron transfer reactions within the mitochondrial respiratory chain.  These 
cofactors span a wide range of midpoint potentials, and are linked together in long chains 
that extend over long distances within these proteins to link together remote catalytic 
sites.      
 1.2.1  Quinones.  There are two main types of quinones found in biological 
systems – benzoquinones and naphthoquinones.  Ubiquinone is a lipid-soluble 
benzoquinone with a long isoprenoid side chain.  Plastoquinone and menaquinone are 
ubiquinone analogs found in plant chloroplasts and bacteria respectively.  Quinones can 
participate in one or two electron transfer processes coupled to the transport of one or two 
protons. Therefore, there are three different redox states that exist for quinone cofactors – 
quinone (oxidized), semiquinone (half reduced), quinol (fully reduced) – and three 
corresponding protonation states for each redox state.  All nine quinone states are 
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depicted in Figure 1.2, though only the states depicted in red have been observed in 
biology.    
 Quinones are regulated in membrane complexes through the stability of their 
semiquinone redox state, which is related to the redox potential difference between their 
	  
Figure 1.2: Thermodynamic box of nine possible ubiquinone redox/protonation states 
(ubiquinone is drawn here without its isoprenoid side chain).  Shown in red are the 
quinone states that have been observed in biological systems, while shown in black are 
thermodynamically unfavored states.  This figure was modified from a similar figure 
shown in the thesis of Bruce Lichtenstein [2]. 	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QH2/SQ and SQ/Q couples.  The stable equilibrium constant for the intermediate 
semiquinone state at complete redox equilibrium is referred to as a semiquinone stability 
constant, or Kstab: 
  
 
Equation 1.1 
Log Kstab values greater than one mean that the semiquinone is a dominant species 
during a redox titration, while log Kstab < -4 means that the semiquinone will be barely 
observable spectroscopically, if at all.   
 1.2.2 Hemes.  Hemes consist of an iron ion coordinated to a large heterocyclic 
organic ring called a porphyrin. The most common porphyrin scaffold in biology is 
protoporphyrin IX (PPIX), otherwise known as heme b. The heme b biosynthesis 
pathway is highly conserved across biological organisms, and is initiated in the 
mitochondrion by the synthesis of D-aminolevulinic acid (dALA) from glycine and 
succinyl-CoA.  
 In addition to heme b, there are two other main forms of hemes found in the 
mitochondrial respiratory chain.  c-type hemes contain a modified FePPIX where the two 
vinyl side chains are uniquely covalently attached to cysteine thiol residues within the 
protein. In the mitochrondrial respiratory chain, heme c is most notably found in the 
cytochrome c1 subunit of Complex III and its redox partner, cytochrome c2.  Heme a is 
found in Complex IV, and is also synthesized through modification of FePPIX. The C-8 
methyl group of FePPIX is oxidized into a formyl group and the vinyl group on C-2 is 
converted into a hydroxyethylfarnesyl side chain.   
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 1.2.3 NAD+ / NADP+.  Nicotinamide adenine dinucleotide (NAD+) and its close 
analog nicotinamide adenine dinucleotide phosphate (NADP+) consist of two nucleotides 
joined by a pair of bridging phosphate groups.  The plus sign in the abbreviations for 
these cofactors does not indicate their net charge, but rather that the nicotinamide ring is 
in its oxidized form with a positive charge on the nitrogen atom.  Both cofactors undergo 
reversible reduction of the nicotinamide ring.  As a substrate molecule undergoes 
oxidation, the oxidized form of the nucleotide accepts a hydride ion (or the equivalent of 
a proton and two electrons) and is transformed into the reduced form (NADH or 
NADPH).  More than 200 enzymes are known to catalyze reactions in which NAD+ (or 
NADP+) accepts a hydride ion from a reduced substrate, or NADH (or NADPH) donates 
a hydride ion to an oxidized substrate.  In Complex I, hydride transfer from NADH to a 
bound quinone cofactor initiates the proton pumping mechanism of the mitochondrial 
respiratory chain.  
 1.2.4 FAD / FADH˙ / FADH2.  Flavin adenine dinucleotide (FAD) consists of a 
riboflavin moiety that is bound to the phosphate group of an ADP molecule.  The fused 
ring structure of the flavin also undergoes reversible reduction, accepting either one or 
two electrons in the form of one or two hydrogen atoms (each atom is the equivalent of 
one electron and one proton) from a reduced substrate.  After one electron transfer 
reaction, like quinones, FAD can form a semiquinone state.  This semiquinone state also 
has an equilibrium-based stability constant related to the two redox couples of the flavin 
moiety.  FAD is covalently bound to Complex II, and is responsible for initiating 
Complex II electron transfer via the oxidation of succinate to fumarate.   
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 1.2.5 FeS cluster.  In FeS clusters, iron molecules are present in association with 
inorganic sulfur atoms or with the sulfur atoms of cysteine residues, or both.  There are 
three main structural motifs of biological FeS clusters, though exceptions do exist in 
hydrogenase enzyme families.  The simplest FeS cluster is the [2Fe-2S] cluster, which is 
comprised of two iron ions bridged by two sulfide ions and coordinated by four cysteine-
based thiol ligands.  [4Fe-4S] clusters feature four iron ions and four sulfide ions placed 
at the vertices of a cubane-like structure.  In these FeS clusters, the iron ions are typically 
coordinated by cysteine thiol ligands.  Finally, proteins also coordinate 3Fe-4S centers, 
which feature one less iron ion than the more common [4Fe-4S] form.  Three sulfide ions 
bridge two iron ions each, while the fourth sulfide bridges three iron ions. Complexes I 
and II each contain combinations of these different types of FeS clusters.  Complex III 
contains a variation of a [2Fe-2S] cluster, where two histidine residues, rather than two 
cysteine thiol groups, coordinate one of the two iron atoms.  This type of [2Fe-2S] cluster 
is named for John Rieske, after the Complex III iron-sulfur protein (ISP) domain was 
isolated in 1964 [25, 26]. 
1.3 Complex III – what we know 
 In 1976, Peter Mitchell developed the Q-cycle theory, which explained how the 
proton coupled electron transfer of Complex III was driven by its ubiquinone cofactors 
[27, 28].  According to Mitchell’s proposal, which also incorporated the previous 
observation of “oxidant-induced reduction of cytochrome b” by Chance [29] and a 
suggested role for semiquinone by Wikstrom and Berden [30], a reduced quinone 
molecule at the interface between the high and low potential chains of Complex III 
(bound at the Qo site) initiates a bifurcated electron transfer reaction upon its oxidation. 
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One electron is accepted by the iron-sulfur cluster (FeS), and follows the c-chain via 
cytochrome c1 to external c-type cytochromes (Figure 1.3).  The other electron passes 
through two b-type hemes and reduces a quinone molecule at the Qi site.  This unique 
	  
Figure 1.3:  Each panel represents a step in the electron and/or proton transfer process 
of one complete Q-cycle (Complex III is represented here as a monomer for 
simplicity).  a) One reduced quinol molecule is delivered to the Qo site from the Q-
pool.  b) The Qo site becomes oxidized, transferring two protons across the membrane 
and distributing two electrons to the high and low potential chains of bc1. c) A proton 
and electron are delivered to the Qi site, forming a stable semiquinone intermediate.  
d) The Q-pool delivers another reduced quinol molecule to the Qo site to restart 
Complex III turnover.  e) The Qo site turns over again, delivering a second set of 
electrons to the high potential c-chain and the low potential b-chain, as well as two 
more protons across the membrane. f) Upon receiving an additional proton and an 
electron from heme bH, the Qi semiquinone becomes fully reduced, and delivers a 
reduced quinol back to the Qpool.  The net result of this cycle is oxidation of one 
quinol, reduction of two cytochromes c, two electrogenic transmembrane electron 
transfers, uptake of two protons from one membrane face and delivery of 4 protons to 
the other. Reprinted with permission from SpringerLink and the Journal of 
Bioenergetics and Biomembranes [3]. 	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electron split sets into motion a quasi-equilibrium state of Complex III that balances the 
redox potentials of the high potential c-chain and low potential b-chain evenly on either 
side of the redox potential of the quinone pool.  This quasi-equilibrium behavior shows 
that Complex III catalysis is rapidly and readily reversible [6].  Collapse of this quasi-
equilibrium into complete equilibrium, in which all chains and pools reach the same 
redox potential, takes place on a tens of seconds timescale and can be assisted by the 
short-circuiting action of redox mediator dyes.  
Under normal forward electron transfer conditions, the efficiency of Complex III 
turnover is high, and deleterious short circuit or bypass reactions involving either Qo or 
heme bL are minimal [31].  Short circuit reactions are defined as any electron transfer 
reaction between two Complex III cofactors that results in an unproductive loss of energy 
[6].  Alternatively, bypass reactions result when the electron transfer processes at the Qo 
site are intercepted by an extraneous reagent, such as oxygen, which steals the electron 
from Complex III and initiates harmful side reactions that produce reactive oxygen 
species [32, 33].   In order for the Qo site to be efficient, these reactions must be 
suppressed, even though the driving forces for these reactions are highly favorable. 
Understanding Qo site engineering means understanding how electron transfer is 
regulated such that productive electron-transfer steps overwhelm unproductive steps.   
1.3.1 Considering Qo movement in its active site.  Crystal structures have 
failed to convincingly resolve oxidized or reduced quinone in the Qo site [34-36]; in fact, 
the Qo site appears to be large enough to potentially accommodate two sequential 
positions for a moving ubiquinone headgroup [24, 37], or conceivably bind multiple 
ubiquinones at the same time [38-40].  However, we do know that whatever the specific 
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electron tunneling distances between Qo-FeS and Qo-bL are, the distances in Complex III 
in general are engineered to allow for millisecond Qo oxidation and avoid short-circuit 
reactions that would be a danger even to a concerted mechanistic model, such as direct 
electron transfer between FeS and bL. 
	  
Figure 1.4  (top panel): Crystal structure of FeS-Qo-bL active sites, drawn from PDB 
file 1PPJ [5].  Heme bL is depicted in red, the FeS cluster is drawn in orange, and two 
Qo site inhibitors myxothiazol (yellow) and stigmatellin (green) are shown bound in 
the Qo site.  Distances between the cofactors were calculated using Pymol, where 23 
Å represents the distance between the FeS cluster and bL , 7 and 11 Å represent 
stigmatellin distances from the FeS cluster and bL respectively, and 13 and 6 Å 
represent myxothaizol distances from the FeS cluster and bL respectively.  (bottom 
panel)  The halftime of bL reduction (s-1) vs. Qo-FeS distance.   	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 Shown in Figure 1.4 are two Qo inhibitor molecules, myxothiazol (yellow) and 
stigmatellin (green), bound at the Qo site, with their respective distances to the other 
cofactors measured using Pymol software [41].  Myxothiazol binds closer to bL in the Qo 
niche than stigmatellin does, and could still allow some quinone to approach the Qo 
pocket distally. This could explain the observations in the literature that myxothiazol has 
no effect on the semiquinone signal attributed to Qo [42], and permits considerably more 
superoxide production by Complex III than stigmatellin [43, 44].    
As described in the Appendix, the Dutton laboratory has developed an electron 
transfer rate expression that offers a simple way to examine parameters that directly 
relate to the oxidoreductase activity of a particular mitochondrial enzyme [1, 45, 46].  
The Moser-Dutton equation defines the rate of electron transfer as a function of distance 
(R), midpoint potential (included in ΔG°), reorganization energy (λ), and protein packing 
density (ρ).  Using this equation, a range of Qo-FeS distances can be considered to 
determine the effect changing the location of Qo in its active site has on the rate of bL 
reduction.  Figure 1.4 depicts the halftime of heme bL reduction vs. Qo-FeS cluster 
distance and demonstrates that millisecond bL reduction rates are maintained as long as 
the Qo-FeS distance falls between 6 and 11 Å at pH 7. Though it is well-established that 
the uphill electron tunneling step between reduced Qo and the FeS cluster is rate-limiting 
as long as Qo falls within this 6-11 Å range [47], should Qo favor binding more closely 
(within 4 Å) to the FeS cluster, Qo to bL electron tunneling becomes rate limiting and 
slows bL reduction by two orders of magnitude.  Likewise, should Qo bind closely to the 
bL heme, Qo oxidation rates are limited by Qo-FeS cluster electron tunneling.  This 
general trend is upheld using equilibrium midpoint potentials at several different pH 
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values, though the reaction rates for Qo oxidation increase as the pH becomes more 
alkaline, increasing the range of FeS-Qo distances that will maintain millisecond 
catalysis.    
1.3.2 Previous models for Qo site mechanism.  Without the direction of 
structural information on Qo binding, a range of mechanistic models has emerged with no 
real consensus as to which one is the most successful.  The work of Osyczka et al. 
prompted revision of all contemporary Q-cycle models in order to accommodate 
suppression of unwanted short-circuits in a reversible, energy-coupling mechanism 
evident in Complex III [6, 48].  However, it was made clear that models that are truly 
concerted two-electron transfer reactions [6], with no detectable semiquinone 
intermediate state on more than a femtoseconds timescale, were not prone to the same 
kind of short circuit possibilities as sequential models that included a semiquinone 
intermediate state [47, 49].  Therefore, all sequential mechanisms that exploit the 
properties of a semiquinone intermediate [24, 48, 50-52], must be modified to include 
effective gating mechanisms, sensitive to different combinations of redox states of the 
FeS, Qo and heme bL redox partners, to promote productive catalysis and prevent 
unproductive short-circuits. 
While there are numerous ways that reversible Q-cycle models can be modified to 
impede short circuits, Osyczka et. al. made it clear that a minimum of two gates or 
barriers are mandatory to regulate Qo redox states.  This model has been amplified by 
Peter Rich, who introduced a double, “logic gated” electron transfer model for Qo site 
electron transfer [52].  In short, this model suggests that reduced quinone is forbidden 
from binding in the Qo site if FeS and heme bL are not both oxidized, and oxidized 
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quinone is forbidden from binding if both of its redox partners are not reduced.  This can, 
in principle, be achieved by regulation of oxidized and reduced quinone binding by 
manipulation of the conformations of Qo hydrogen bonding partners by the redox and 
protonation states of heme bL and FeS (see also [6, 48].   
Crofts et al. modified their sequential mechanism [53] to introduce more redox-
state sensitive gating to avoid short circuits [24, 50].  They propose that when a 
semiquinone intermediate is formed, it can move closer to oxidized heme bL and 
participate in productive electron transfer. However, when heme bL is reduced, there is a 
Coulombic repulsion which keeps the semiquinone away from reduced heme bL, towards 
the FeS end of the site, and inhibits the unproductive, and energetically favorable, short-
circuit reduction of semiquinone by heme bL.  While in principle Coulombic interactions 
could provide a redox-state sensitive gate to inhibit a short-circuit reaction, more than one 
gate is needed.  The Coloumbic push of semiquinone from reduced heme bL moves it 
closer to FeS, which when oxidized, can accept an electron from the semiquinone in 
another type of short circuit.  A second gate for this type of model requires the FeS and 
semiquinone to overcome their coulombic attraction and enter some sort of conformation 
to prevent energetically favorable, but wasteful electron transfer.  In addition, the site 
must be designed to overcome a coulombic repulsion between semiquinone and reduced 
FeS.  This would allow a favorable interaction between semiquinone and reduced FeS, 
fostering productive and rapid reverse reactions in which oxidized quinone is doubly 
reduced by FeS and heme bL 
 1.3.3 Possibilities for Qo site thermodynamics.  The thermodynamics of 
concerted and sequential mechanisms are distinctly different even in wild-type Complex 
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III.  Figure 1.5 illustrates that the energetic landscape for a concerted mechanism at Qo 
has an activation barrier that depends on both FeS and heme bL redox midpoint 
potentials[3].  In this mechanism, the activation barrier for forming the semiquinone 
	  	  
Figure 1.5: Electron transfer reaction energy surfaces for Qo site operation by 
concerted and sequential mechanisms.  Marcus-like parabolic potential surfaces are 
shown for each redox state. In a concerted reaction (top), electron transfer to form a 
semiquinone state (purple) takes more thermal energy than forming the two-electron 
transition state.  In a sequential mechanism (middle), electron transfer to form a 
semiquinone intermediate state takes less energy than the simultaneous two electron 
transfers, but leaves Complex III potentially exposed to highly exergonic short-circuit 
reactions such as the one illustrated in the bottom panel.  Reprinted with permission 
from SpringerLink and the Journal of Bioenergetics and Biomembranes [3]. 	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intermediate (purple curve) is significantly higher; normally semiquinone formation 
would be minimal, but not impossible.  In contrast, the sequential mechanism will have a 
reduced quinone oxidation rate that depends on either the midpoint potential of the FeS 
or the heme bL.  Experimentally, changing the midpoint potential of the FeS often 
changes the rate; however, changing the heme bL midpoint potential has proven more 
difficult and the changes that have been made are modest. Thus, how or if the heme bL 
midpoint potential affects the rate is still unclear.  
The bottom panel of Figure 1.5 illustrates the energetic picture of one of the short-
circuit reactions [3].  The rapid reversibility of the reactions at the Qo site means reverse 
electron transfer is on roughly the same timescale as the forward reaction, and will 
reform the same amount of semiquinone that is formed by the initial electron transfer 
between Qo and the FeS cluster. However, the short-circuit reduction of reoxidized FeS 
is highly favorable and energetically disastrous; if Complex III is operating by a 
sequential mechanism, redox-state activated gates must be present to avoid unproductive 
short-circuit reactions.   
 1.3.4 Previous attempts to isolate SQo.  Direct observation of a Qo 
semiquinone state has proven to be extremely controversial due to the limitations in 
measuring such an unstable state.  In 1979, Takamiya and Dutton redox-poised R. 
sphaeroides membranes and extracted the quinone cofactors to determine the amount of 
quinone oxidized and the amount reduced as a function of poised redox potential [54].  
From these experiments, they defined the size and redox potential of the quinone pool: 19 
out of 25 quinones per reaction center had a midpoint potential at pH 7 of 90 mV.  They 
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also examined the redox-poised membranes for evidence of a Qo semiquinone by EPR 
spectroscopy, but did not detect a clear signal. 
de Vries et al. announced the trapping of a Qo semiquinone in mitochondrial 
Complex III as a 2,3-dimercaptopropanol (BAL)-sensitive signal uncovered under non-
equilibrium conditions [55].  BAL chelates heavy metals and is suggested to destroy the 
Rieske FeS center, allowing for a direct probe of the Qo site.  Compared with the 
antimycin-sensitive semiquinone signal discovered at Qi (g = 2.005, 10 G wide) [56], the 
signal attributed to Qo in these experiments was narrower (8.8 G), had a slightly different 
g value (2.006), and required less power to saturate.  Since this signal was obtained using 
non-equilibrium methods, the redox midpoint potential of the semiquinone couples could 
not be determined.  However, Junemann et al. revisited these experiments and revealed 
that de Vries’s semiquinone signal was insensitive to a more modern collection of Qo site 
inhibitor compounds, such as myxothiazol, MOA-stilbene, and stigmatellin [57].  
Therefore, based upon this evidence, it remains unlikely the data published by de Vries et 
al. was indicative of a Qo semiquinone state.   
In recent years, two new EPR-based approaches emerged and revealed 
semiquinone signals that were sensitive to stigmatellin, a tight binding Qo site inhibitor.  
The first approach was explored by Cape et al. using anaerobic freeze-quenching 
techniques after rapid mixing of antimycin-inhibited Complex III isolated from R. 
capsulatus with decylubiquinone in the Qo active site [32].  This stigmatellin-sensitive 
signal had a g-value of 2.0054 with a 11.9 G line width.  Although this signal does appear 
at or near the Qo site, it does not appear to have a clear magnetic interaction with the 
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Rieske FeS cluster, raising questions about whether or not it is representative of a true Qo 
semiquinone intermediate. 
The Dutton laboratory explored the second approach; their experiments used 
light-activated photosynthetic membranes with heme(s) bL and/or heme c1 knocked out, 
deliberately driving the thermodynamics of Qo to maximize semiquinone production 
[42].  After a series of light flashes, the high potential c-chain became highly oxidized in 
this system, stimulating the oxidation of Qo by the quinone pool and loading the low 
potential b-chain with reducing equivalents.  This experimental setup, where the high 
potential chain is very oxidized, proved to be very favorable for stripping an electron 
from a second quinol at Qo to form a semiquinone.  The g-value of the signal observed 
under these conditions was determined to be 2.0040 and the line width was 11.7 G.  
Because the stoichiometry of the redox components involved in the pseudo-equilibrium 
between the b- and c-chains and the quinone pool was known, the split between the redox 
couples for this quinone species was estimated to be approximately 880 mV, with the 
QH2/SQ couple ~410 mV at pH 9.  Therefore, from this data the effective stability 
constant for Qo was estimated to be 10-15.  However, this data was obtained using 
chromatophore membranes with massive mutational changes (cofactor knockouts), 
causing many in the field to argue that this signal, even if it was attributable to a Qo 
semiquinone, was not indicative of a mechanistic state that could be observed in wild-
type chromatophores.   
Even though an EPR signature attributed to a Qo semiquinone has been 
experimentally isolated and characterized, it is not yet clear if this is a legitimate, 
transient mechanistic intermediate, or a side reaction forced into existence by 
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experimental design.  Therefore, it is still too soon to reject the possibility that the normal 
Qo site mechanism is concerted, with the transfer of both electrons occurring in a very 
short interval, leaving no time for an oxidized quinone to relax into any intermediate 
state.    
 1.3.5 Complex III activity is unaffected by Qo binding site mutations.  The 
Qo site mechanism is also surprisingly resilient to mutational modifications at the Qo 
site.  Though the mostly conserved glutamate (E) of the Qo active site PEWY sequence is 
often given a carefully orchestrated role controlling the proton transfer reactions of QH2 
oxidation at the Qo site [24, 50], replacement of the glutamate group with non-polar or 
even basic groups had almost no effect on any of the equilibrium properties of the Qo site 
or its redox partners [51].  As the Qo site appears to have residue redundancy that 
compensates for mutagenic changes easily, a specific network of protons within the 
active site may not be necessary for preserving productive Qo site electron tunneling.  
Instead, the tunneling network itself must be designed to raise barriers that suppress 
unwanted short circuit reactions. 
 1.3.6 Redox properties of the quinone sites in Complex III.  The bifurcated 
electron transfer that occurs within Complex III is completely dependent upon its ability 
to modify the redox environment of the ubiquinone pool at each of its quinone binding 
sites, Qo and Qi. The environment of the Qi binding site forces the quinone redox 
couples to be very similar. The redox couples and stability constant for Qi have been 
measured (log Kstab is -2.3 at neutral pH) using EPR spectroscopy, and under mildly 
alkaline conditions, the redox midpoint potentials of the oxidized quinone, semiquinone, 
and fully reduced quinol can reach equilibrium at equal one third concentrations.  At Qo, 
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the first electron is removed from the reduced quinol at a relatively oxidizing midpoint 
potential to head down the high potential c-chain, while the second electron is removed at 
a relatively reducing midpoint potential and is transferred to the low potential b-chain.  
Therefore, unlike Qi, the redox couples at Qo have a very large difference in midpoint 
potential, and a very low Kstab value. 
 As shown in figure 1.6, there are eight possible combinations of redox states for 
Qo and its redox partners, heme bL and FeS.  Half of these states are equilibrium states 
readily achieved by simple redox poising (shown in black), and half are non-equilibrium 
states have yet to be experimentally characterized (shown in red and green). The green 
states are particularly important since they are the enzyme-substrate and enzyme-product 
	  
Figure 1.6: Eight possible redox state combinations for the Qo site and its electron 
transfer partners, FeS and heme bL.  Equilibrium states are shown in black, productive 
transient intermediates are shown in green, and non-physiological quasi-equilibrium 
states are shown in red.  Solid lines indicate closed gates, and solid lines with a break 
in the middle indicate open gates for electron transfer.  Dashed lines indicate that a 
gating mechanism is optional for this electron transfer. Reprinted with permission 
from SpringerLink and the Journal of Bioenergetics and Biomembranes [3]. 	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states immediate to physiologically productive quinone oxidation- and reduction-coupled 
energy transduction at the Qo site, while the states shown in red are subject to short-
circuit reactions that are high in driving force and physiologically unproductive. 
Assuming a sequential-gated Qo site mechanism in this model, the gates controlling 
semiquinone activity must be open so that catalysis can occur in the green states, while 
the gates are closed in the red states in order to protect Complex III from short circuiting. 
 1.3.7 Redox properties of other Complex III cofactors. Understanding the 
engineering design of Complex III and the operating limits of failure of the Q-cycle 
requires an understanding of the redox properties of each redox-active component.  The 
redox properties of the cofactors in Complex III are well-described by redox titrations 
performed across a wide range of pH values, as shown in Figure 1.7 [4].  The FeS cluster 
has a pKox near neutral pH in both R. capsulatus and R.sphaeroides.  Cytochrome c1 has 
pKox and pKred values close to one another near neutral pH, and a weak pH dependency 
(much less than 1 H+ / 1 e-).  Previous measurements of the Qpool size and redox 
properties are included on the left graph as a green dashed line [54], and Qi redox 
properties were also previously measured under conditions where its semiquinone 
species is readily accessible by EPR measurements [58]. 
 The Dutton [4] and Crofts [50] laboratories have measured redox prorperties of 
the b-hemes in recent years. Original redox titrations of the b-hemes revealed three redox 
active species [59], which are now resolved in Figure 1.7 as bL and two different forms 
of bH - bH high and bH low.    Heme bL displays a strong coupling to protons at acidic pH 
values, and is pH independent at pH values more alkaline than its pKred (pH ~ 8.5).  
These redox properties are unchanged in the presence of the Qi inhibitor antimycin.  The 
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redox behavior of bH is directly coupled to the redox state of Qi, and is also altered when 
antimycin is bound to the Qi site.  80% of heme bH centers are in the low potential form 
at acidic pH values, though this number is reduced to 55% at alkaline pH values [4]. 
1.4 Developing a simple tunneling view of Complex III activity 
 The redox midpoint potentials and electron tunneling distances of the cofactors in 
Complex III were inputted into the Moser-Dutton equation to calculate ket.  These rates 
are used to present an an elementary view of Complex III electron tunneling that is 
expanded upon experimentally in chapter two.   
 1.4.1 A single turnover view of Complex III electron tunneling.  Figure 1.8 
shows a single, two electron turnover of Complex III when all of its redox components 
are oxidized except for the Qo site, with its measured 10-15 Kstab constant [42] providing 
	  
Figure 1.7: Redox midpoint potentials of the components of Complex III in two 
different species of photosynthetic bacteria as a function of pH, as determined 
experimentally by Haibo Zhang. Reprinted with permission from SpringerLink and 
the Journal of Bioenergetics and Biomembranes [4]. 	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for millisecond catalysis of quinone oxidation.  FeS is modeled as moving between two 
sites, distal and proximal to the Qo site with a rate of about 105 s-1 [60].  Heme bL is only 
transiently reduced as the electron comes to reside on heme bH and Qi.  Also, when the 
	  	  
Figure 1.8:  Electron tunneling calculations for Complex III. Shown on the left  (A, C, 
E) are rate calculations that assume that Complex III is functional as a monomer, and 
shown on the right  (B, D, F) are those for a functional dimer.  Dashed lines in the 
right-hand side graphs represent the redox centers in the second half of the dimer 
introduced into the calculations.  (A and D) All redox centers considered.  (B and E)  
Calculating all centers except Qi, which has been effectively “inhibited” by extending 
the electron transfer distance to 50 Å.  C and F)  Considering site directed mutants 
where heme bH is not incorporated [6].  Figure modified from data presented in 
Biochimica et Biophysica Acta – Bioenergetics [1]. 	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electron can get as far as Qi, short-circuit reactions through reverse reactions and a Qo 
semiquinone are slowed to a minutes timescale.   
   These calculations can be modified to include inhibitors or mutations that limit 
Complex III turnover.  For example, the addition of antimycin at the Qi site or bH 
knockout mutations can be considered in our system of rate equations.  Heme bH 
reduction is dominant in the presence of antimycin, with short-circuits still taking place 
relatively slowly on a tens of seconds timescale (under non-membrane energized 
conditions), representing what is observed under single turnover flash experiments.  
However, when heme bH is knocked out, the electron cannot escape from bL and is prone 
to millisecond short-circuit reactions that are comparable to the rate of catalysis.  Because 
rapid short-circuit reactions are not observed experimentally in these knockouts, the 
redox couples of Qo (and therefore, its stability constant), must be modulated in some 
way to allow catalysis in certain redox states while making the semiquinone (and 
therefore, short-circuit reactions) inaccessible in others.   
 Structurally, Complex III is a dimer, but whether or not it acts as a functional 
dimer remains controversial.  We can compare Complex III as a functional monomer or 
dimer using the Moser-Dutton equation.  With an edge-to-edge spacing of 14.7 Å 
between the two heme bL cofactors, functionally significant electron tunneling between 
the two halves of the dimer could take place on a reasonable timescale.  This is shown in 
the right panels of Figure 1.8, mirroring the conditions described above.  Redox 
equilibration of the low potential chains is shown to take place on a seconds timescale, 
depending upon the presence of Qi.  Short-circuit reactions occur in both halves of the 
dimer, even though reduced quinone has only been introduced at one of the Qo sites.  
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However, with the same fixed stability constant, of 10-15, the heme b knockout allows the 
electron to linger on bL, with cross-dimer redox equilibration occurring on a millisecond 
timescale.  Therefore, the electron tunneling contact between both halves of the dimer is 
occurs on the same timescale as catalysis, indicating that Complex III has effectively 
increased the concentration of active Qo sites available when the complex is partially 
reduced. 
1.5 Finding new ways to study an old problem 
 It has been decades since Peter Mitchell developed the Q-cycle mechanism with 
little resolved about the mechanism of Qo turnover in Complex III.  In order to address 
these unanswered questions, the field of bioenergetics must develop a fresh perspective 
and new experimental techniques. In chapter two, R. sphaeroides Complex III proteins 
with modifications to their heme c1 are studied to understand how Complex III redox 
reactions within the high and low potential chains are interconnected.   
 This thesis also applies the principles of de novo protein design towards 
developing a new model system to study Complex III turnover.  In chapter three, the 
development and characterization of the first functional amphiphilic maquette, AP6, is 
presented.  AP6 extracts the basic engineering requirements from the b-subunit of 
Complex III to perform proton-coupled electron transfer across a membrane interface.   
In chapter four, AP6 enzymatic function is quantified using standard Complex III activity 
assays, and AP6 is revealed as the first maquette to achieve activity within two orders of 
magnitude of a natural protein system.  Manipulating the thermodynamics of the rate-
limiting quinol to heme electron transfer step in this maquette system is explored in 
chapter five.  Finally, chapter six will conclude with the development of a simple model 
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for Complex III that can be applied by the field of bioenergetics to study specific Qo 
redox states. 
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Chapter 2:  Mutations to heme c1 binding site 
residues reveal R. sphaeroides Complex III 
activity is robust 
 
 
 
 
 
 
 
 
It is becoming increasingly clear that electron transfer chains in natural proteins are not 
finely tuned, but robustly designed to transfer electrons between catalytic sites and 
survive the many obstacles of mutational change during evolution and natural selection.  
In this chapter, mutational work at heme c1 has revealed that the reversible electron 
transfer chain in R. sphaeroides Complex III is engineered to withstand large changes in 
active site residues and midpoint potential to preserve turnover.  The impact of altering 
these motifs in R. sphaeroides was tested as a means to explain how heme c1 can 
maintain its function in response to massive changes in R. sphaeroides ligation, while the 
midpoint potential of R. capsulatus c1 cannot avoid collapsing to a dysfunctional level.  
This work is part of a first-author manuscript in preparation to Biochemistry [1]. 
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2.1 Introduction 
 A critical part of maintaining the productive energy-conversion observed in 
Complex III is the protection against electronic and protonic short circuits between 
reactive intermediates subsequent to charge separation [3, 4].  By promoting 
macroscopically reversible energy coupling, Complex III has several unproductive short 
circuits to defend against within the Qo site, and cannot rely upon the high driving force 
and practical irreversibility used by photosynthetic reaction centers as a defense.    
 2.1.1  Mutations at the heme c1 binding site.  Though the seemingly 
complicated Qo bifurcation electron transfer reaction should have specific 
thermodynamic requirements for the rest of the redox cofactors in Complex III in order to 
avoid these short circuit reactions, surprisingly, Complex III turnover is rarely affected by 
substantial midpoint potential changes within the high potential chain. While the CXXCH 
motif found in R. sphaeroides is the consensus motif for high potential class I c-type 
cytochromes, previous work has demonstrated that the heme c1 found in this system is 
very tolerable to changes in its sixth axial ligand methionine [5].  This tolerance was 
described as a gradual decrease in the midpoint potential of heme c1 as the methionine 
residue is varied, with only a M185H mutant rendering the midpoint potential too low for 
Complex III to remain functional.   
 Both R. capsulatus and R. sphaeroides c1 subunits contain a disulfide-secured 
loop near the heme binding site that has been identified to support high c1 midpoint 
potentials [2, 5, 6].  However, surprisingly, the threshold for making changes to the c1 
sixth ligand in R. capsulatus is significantly lower than that of R. sphaeroides.  It has 
been proposed that the β−branched amino acid that directly precedes the heme ligating 
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position in R. sphaeroides increases both solvent inaccessibility and protein packing 
within the c1 subunit and helps to maintain a higher c1 midpoint potential even after 
changes to the methionine residue are introduced.  In fact, adding a β-branched amino 
acid motif to R. capsulatus can repair incompetent midpoint potentials caused by 
breaking the disulfide loop [6].    	   2.1.2  Inhibition of heme c1.  Adding inhibitors to the quinone sites has been 
used to isolate electron transfer reactions in the low-potential chain of Complex III and 
control the flow of electrons. Stigmatellin [7, 8] and myxothiazol [9] can be added to 
inhibit Qo oxidation, and antimycin inhibits Qi reduction [10]. However, these inhibitors 
do block Qo and Qi from their active sites, making it impossible to isolate and describe 
specific quinone catalytic events when inihibitors are bound. 	   Reversible inhibition of the hemes in Complex III would allow the isolation of 
sequential electron transfers to be extended to the high-potential chain of Complex III 
without sabotaging Qo site oxidation.  Photo-dissociable small ligands, such as carbon 
monoxide (CO) are ideal inhibitors of heme c1 because their dissociation rate from heme 
c1 would be on the same timescale as enzyme turnover, enabling normal electron transfer 
between the FeS cluster and heme c1.  Additionally, the formation of a heme c1-CO 
complex would provide a unique experimental opportunity to light-activate Complex III 
in the absence of other chromatophore proteins, such as the reaction center.  This would 
simplify current light-activation experiments that involve chromatophore membranes that 
contain several redox proteins (that can have overlapping spectral properties).  Though a 
heme c1-CO complex has never been formed in wild type Complex III, heme c1 has 
proven to be amendable to ligation with other small molecules.  Oxidized heme c1 in R. 
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capsulatus Complex III has been demonstrated to reversibly bind cyanide with high 
affinity and shift the heme midpoint potential dramatically [11].   
2.2 Materials and Methods   
 2.2.1 Bacterial strains and growth. Mutations to Complex III heme c1 binding 
site residues were constructed by Haibo Zhang using the Quikchange site-directed 
mutagenesis system (Stratagene) as described previously [12].  These mutants were 
stored as glycerol stocks at -80 º C. 
 50 µL of R. sphaeroides glycerol stocks were plated on agar plates with Sistrom’s 
Minimal Media A and 10 µM tetracycline.  Plates were incubated for 2 days at 37 º C.  25 
mL of autoclaved Sistrom’s Minimal Media A with tetracycline added was inoculated 
with a single colony from the plate, and these flasks were agitated in the dark at 37 º C 
and 200 rpm overnight.  10 mL of this culture were transferred to 1 L of growth media 
and agitated in the dark for an additional day at 37 º C and 200 rpm.   
 2.2.2 Chromatophore membrane / protein purification.  Growth media was 
centrifuged at 5000 rpm for 30 minutes and cell pellets were collected.  Cell pellets were 
resuspended in 90 mL of equilibration buffer (100 mM NaCl, 50 mM Tris pH 8, 20% 
glycerol).  Phenylmethanesulfonylfluoride (PMSF) (Sigma) was added to the solution at a 
final concentration of 2 µM, and the solution was French pressed to break the cell 
membranes.  Cells were centrifuged at 10,000 rpm for 45 minutes, and the supernatant 
was collected for ultracentrifugation.  The solution was spun at 45,000 rpm for 2 hours, 
and the chromatophore pellet was collected and resuspended in 25 mL of equilibration 
buffer for purification.  
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 Complex III proteins were purified from chromatophore membranes using a 
BioGel A DEAE ion-exchange column (Bio-Rad).  The column was equilibrated with 
five column volumes of equilibration buffer and 10 mL of the protein sample was loaded 
onto the column.  The column was washed with two column volumes of equilibration 
buffer and then a 200 mL salt gradient of 150 mM to 600 mM NaCl was used to elute 
Complex III (buffers also contained 50 mM Tris pH 8 and 20% glycerol).  Complex III 
eluted between 375 – 400 mM NaCl.  The fractions that contained Complex III were 
pooled and dialyzed against a low salt buffer overnight and then concentrated to 5 mL of 
purified protein. Reduced minus oxidized UV-visible difference absorption spectra 
(Figure 2.1) were collected for each of the Complex III mutant proteins in this study.   
 2.2.3 Flash-induced single turnover kinetics.  Flash-induced single-turnover 
time-resolved kinetics were performed according to [13] using chromatophore 
membranes and a double-wavelength spectrophotometer (Biomedical Instrumentation 
	  
	  	  
Figure 2.1: Difference UV-visible absorption spectra of Complex III wild type and 
heme c1 mutant proteins.  Both spectra are the difference in absorption between 
reduced Complex III and oxidized (using potassium ferricyanide).  The dotted line 
represents the samples reduced with ascorbate and the solid line represents samples 
reduced with dithionite. 	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Group, University of Pennsylvania, Philadelphia, PA) in the presence of 2.5 µM 
valinomycin, 8 µM 2,3,5,6-tetramethyl phenylenediamine, 2.5 µM  phenazine 
methosulphate, 2.5 µM phenazine ethosulfate, 6 µM 1,2 naphthoquinone, 6 µM 2-
hydroxy-1,4-naphthoquinone, 100 µM ferrocyanide and 70 µM benzyl viologen. 
Transient cytochrome c re-reduction kinetics initiated by a short saturating flash (8 µs) 
from a xenon lamp was followed at 552-540 nm. The concentration of antimycin, 
myxothiazol and stigmatellin used were 5, 5 and 1 µM, respectively, and the ambient 
potential was poised at 100 mV or 250 mV. 
2.2.4 Redox titrations of heme c1 mutants. Equilibrium redox potentiometry 
was used as a functional analysis of the oxidation and reduction of heme c1 [14].  Redox 
titrations were performed in an anaerobic 1 mL cuvette (Starna Cells) equipped with a 
silver / silver chloride and platinum combination electrode (Microelectrodes Inc.). All of 
the potentials reported are in reference to the normal hydrogen electrode (NHE).  The 
reduction potential of the cuvette solution was adjusted by adding microliter aliquots of 
freshly prepared solutions of either sodium dithionite (for reducing) or potassium 
ferricyanide (for oxidizing). 20 µL of a stock solution containing the following redox 
mediator dyes was also added to the solution (final concentrations reported): 2.5 µM 
valinomycin, 8 µM 2,3,5,6-tetramethyl phenylenediamine, 2.5 µM  phenazine 
methosulphate, 2.5 µM phenazine ethosulfate, 6 µM 1,2 naphthoquinone, 6 µM 2-
hydroxy-1,4-naphthoquinone, 100 µM ferrocyanide and 70 µM benzyl viologen. After 
equilibration at each midpoint potential, the UV-visible spectrum of Complex III was 
recorded, monitoring in particular the increase in the sharp α-band absorption at 550 nm 
relative to a 540 nm reference wavelength. 	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 2.2.5 CO binding.  3 mL of 5 µM Complex III was added to a UV-visible quartz 
cuvette and purged with argon. A concentrated dithionite solution was titrated in 1 µL at 
a time until the protein was fully reduced (5-6 µL).  10 mL of CO gas was added to the 
cuvette in the hood with a gas-tight syringe.  The solution was monitored for up to two 
hours to determine the extent of CO ligation, if any. 	   2.2.7 Reduction of decylubiquinone (DBH) substrate. Quinols were prepared 
from the oxidized quinone using the method described by Peter Rich [15].  0.25 g 
decylubiquinone was dissolved in 50 mL diethyl ether and placed in a separatory funnel. 
A solution of 1 g sodium dithionite in 50 mL water was added and the mixture was 
shaken together. The quinone could be seen to initially increase in yellow color due to 
semiquinone formation, but eventually became colorless as full reduction to quinol 
occurred. The ethereal layer was shaken with a second 50 mL solution of sodium 
dithionite to ensure completion of the reduction reaction. After removal of the dithionite 
solution, the ethereal layer was washed twice with a saturated sodium chloride solution. 
The ethereal layer containing quinol was then passed through 30 g anhydrous sodium 
sulfate in a sintered glass funnel to remove any residual water, and the ethereal solution 
was then dried down by rotovaporization at 25°C.  The resulting white powder was 
dissolved in an acidic ethanol solution (95% ethanol containing 10 mM hydrochloric 
acid) and flash frozen in 500 mL aliquots.  
 2.2.8 Steady-state measurement of Complex III activity. Complex III activity 
was measured using a standard assay developed by Trumpower et al [16].  A solution of 
25 mM horse heart cytochrome c (Sigma) in redox buffer (50 mM potassium phosphate 
and 100 mM potassium chloride at pH 8) and 10 µM decylubiquinone was incubated in a 
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3 mL cuvette saturated with CO gas and stirred for one minute, after which CO-inhibited 
Complex III was introduced into the cuvette in nanomolar concentrations (10-100 nM). 
Using an extinction coefficient of 18.5 mM-1cm-1 for the 551 nm – 540 nm difference 
absorption, cytochrome c reduction was monitored over time until the amount of 
cytochrome c reduced reached a constant maximum.  
2.3 Results 
 Sixth ligand mutagenesis of heme c1 caused electron tunneling at heme c1 to 
become the rate limiting step in ubiquinone oxidation at the Qo site, establishing an 
unfavorable redox equilibrium limit (three to four orders of magnitude) for Complex III 
catalysis [5].  However, Complex III can tolerate a remarkably wide range of energy 
barriers before turnover is halted, demonstrating that electron transfer reactions carried 
out by long chains of cofactors are undeniably robust.   This work explored whether the 
disulfide loop residues found in the R. sphaeroides binding site are responsible for 
stabilizing heme c1 midpoint potential.  Mutations C145A, C169A, and C145AC169 did 
not significantly impact Complex III activity or heme c1 midpoint potential, indicating 
that these residues do not play an active role in stabilizing the midpoint potential of heme 
c1 or modulating the thermodynamics of FeS cluster to heme c1 electron transfer.   Table 
2.1 summarizes the general characteristics for each of the disulfide mutants.  
Representative flash kinetic traces and redox titrations for the mutant proteins are 
reported as C145A data. 
 2.3.1 Flash kinetics of cytochrome c1 + cytochrome c2.    Using light-activated 
chromatophores, the kinetics of specific redox reactions within Complex III can be 
monitored following a short flash.  The electrons delivered from the flash of light activate  
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Table 2.1 Mutagenesis of cysteine residues in Rb. sphaeroides Complex III 
 
the photosynthetic reaction center and go on to create the two substrates of Complex III, 
oxidized cytochrome c2 and hydroquinone, within microseconds. 
 Figure 2.2 compares the flash-induced cytochrome c oxidation and re-reduction in 
wild type and the C145A mutant measured under the conditions which preset cytochrome 
c and FeS reduced and the quinone pool half-reduced before activation at 100 mV. 
Kinetic traces without any inhibitor and with two potent Qo site inhibitors, myxothiazol 
and stigmatellin, are shown. In all cases, the flash-induced cytochrome c oxidation 
(cytochrome c1+c2, which is not resolved in the experiment) is rapid, with a time constant 
beyond the resolution of the instrument.  
 The Qo site inhibitors provide a useful means of measuring the levels of different 
phases of cytochrome reduction. Stigmatellin, which completely inhibits the Qo site 
activity as well as fixes the FeS cluster in its b-position docked onto cytochrome b [17, 
18], reveals the full level of oxidation of cytochrome c by flash activated reaction center 
Mutation Phenotype (a) 
Em7 
(mV) (b) 
bH reduction 
rate (s-1) (c) 
CO 
binding 
(d) 
Reversion to Ps+(e) 
Wild type PS+ 281 856 - N/A 
C145A PS+ 276 836 - N/A 
C169A PS+ 278 892 - N/A 
C145A_C169A PS+ 285 840 + N/A 
 
(a) Ps+ and Ps- indicate photosynthetic competence and incompetence, respectively. 
(b) Midpoint redox potential of cytochrome c1 in purified Complex III. (c) bH reduction 
rates were determined by flash kinetics at the ambient potential of 100 mV at pH 7.0 
by recording the absorbance changes at 560-570 nm, and fitting them to a single 
exponential equation. (d) (+) and (-) indicate the ability of ferrocytochrome c1 in 
isolated Complex III to binding carbon monoxide. (e) Spontaneous site suppressor 
mutations in cytochrome c1 that restore photosynthetic activity of the cells. 
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(green traces in Figure 2.2). Myxothiazol, which also inhibits the Qo site but has no effect 
on the FeS cluster movement, normally does not reveal the portion of cytochrome that 
becomes rapidly reduced by pre-reduced FeS cluster. Thus, the offset in the amplitude of 
cytochrome c oxidation with the stigmatellin and myxothiazol, seen clearly in wild-type 
Complex III, is attributed to this initial phase of the cytochrome c re-reduction.  C145A 
displays very similar heme c1 kinetics as the wild-type Complex III protein.  With no 
inhibitors present, the re-reduction of heme c1 occurs at 143 s-1 in the C145A mutant, in 
comparison to 167 s-1 for wild-type Complex III.   
	  
Figure 2.2:  Flash kinetics of heme bH and cytochrome c in chromatophores from wild 
type Complex III and a C145A mutant. The ambient redox potential was poised at 100 
mV at pH 7.0. The kinetics of the flash-induced cytochrome c were followed at 551-
540 nm (a, c), and the kinetics of the flash-induced heme bH were followed at 560-570 
nm (b, d). The kinetic traces completed in the absence of inhibitors are shown in 
black.  The Qi site reaction was inhibited with antimycin (red), the Qo site was 
inhibited with myxothiazol (blue), and in the control experiment, both Qi and Qo site 
activity were inhibited with antimycin and stigmatellin (green). 	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 2.3.2 Flash kinetics of heme bH. Using antimycin to completely inhibit electron 
transfer at the Qi site [10] sets up a sensitive test for how changing the binding site 
residues at heme c1 impact the rate of the Qo site bifurcation reaction and subsequent 
redox equilibrium.  Figures 2.2 and 2.3 shows the time-course of flash-induced heme bH 
reduction in wild-type Complex III and the C145A mutant at two different driving force 
conditions by changing the ambient redox potential prior to activation.  
 First, the redox potential of the chromatophores was poised at 100 mV, which 
creates a state where the Q-pool is half-reduced and close to the potential of the Qo site 
prior to the flash.  In the presence of antimycin, the reduction of heme bH takes place on a 
millisecond timescale in both wild type Complex III and the C145A mutant.  In a second 
experiment, chromatophores were poised at 250 mV prior to the flash.  Under this 
	  
Figure 2.3: Flash kinetics of heme bH and cytochrome c in chromatophores from wild 
type Complex III and a C145A mutant. The ambient redox potential was poised at 250 
mV at pH 7.0. The kinetics of the flash-induced cytochrome c were followed at 551-
540 nm (a, c), and the kinetics of the flash-induced heme bH were followed at 560-570 
nm (b, d). The kinetic traces completed in the absence of inhibitors are shown in 
black.  The Qi site reaction was inhibited with antimycin (red), the Qo site was 
inhibited with myxothiazol (blue), and in the control experiment, both Qi and Qo site 
activity were inhibited with antimycin and stigmatellin (green). 	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condition, the Q-pool is fully oxidized and reduced quinone is only available after flash 
activation of the reaction centers, diffusing through the Q-pool before binding to the Qo 
site.  For wild type, this diffusion is the rate-limiting step in the overall reaction at this 
high redox potential, and heme bH reduction is slowed relative to when the system is 
poised at lower redox potential.  C145A actually demonstrates slightly faster bH reduction 
kinetics under these condtions, with a rate of 119 s-1 compared to 77 s-1 in the wild-type 
Complex III. 
 2.3.3  Heme c1 – CO.  The ability of the mutant proteins to bind CO was tested to 
determine if any of the heme ligands were disrupted by eliminating the disulfide bridge.  
	   	  
Figure 2.4:  UV-visible spectra for reduced wild-type (a) and two cysteine mutant 
proteins, C169A (b) and C145A (c), before (solid line) and after (dashed line) the 
addition of CO to the cuvette.   	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Figure 2.4 shows the UV-visible absorbance spectra for wild-type, C145A, and C169A 
proteins before (solid line) and after (dashed line) treatment with CO.  The difference 
between the dithionite reduced + CO spectra minus the dithionite reduced spectra is 
equivalent for all of the proteins, indicating that the ligands of heme c1 are not affected by 
mutating the disulfide bridge residues.  This is disappointing because of the experimental 
advantages that could be gained from a light-activatable ligand in the high potential 
chain, but not surprising given the mutants behaved so similarly to wild-type heme c1. 
 If left under a constant stream of CO gas for two or more hours, reduced wild-
type Complex III does begin to demonstrate more significant spectral changes due to the 
presence of CO in the cuvette.  The Soret band blue shifts 5 nm from the reduced Soret 
band found at 424 nm, and the characteristic b-heme α-band signature also begins to 
decrease.  These samples were tested for Complex III activity using the steady-state assay 
developed by Trumpower et al [16] and were found to have diminished Complex III 
activity even after the CO has been removed from the sample.  Therefore, even on longer 
timescales, it is not likely that wild-type heme c1 ligates a CO molecule to heme c1.  
Instead, these changes could either be associated with a slow re-oxidation of the protein 
or gradual destruction of the b-hemes by CO.   
2.4  Discussion 
 2.4.1  Heme c1 binding motifs are not required for midpoint potential 
stability.  Not surprisingly, just as R. sphaeroides is more resilient to changes in its 
disulfide loop region, it can also withstand mutations to its β-branched amino acid 
without losing functionality.  Single and double cysteine mutants that break the disulfide 
bridge within the c1 heme-binding motif are still photosynthetically competent and retain 
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high c1 midpoint potentials (Table 2.1). Additionally, a double mutant that breaks the 
disulfide loop and eliminates the β-branched isoleucine is also surprisingly still 
physiologically competent [2].    
 Elberry et al. also reported experimental mutations in disulfide bridge residues 
still resulted in Complex III functionality [2]; however, they report extremely low heme 
	  
Figure 2.5: Redox titrations of wild-type and C145A Complex III proteins in different 
buffer conditions.  These titrations are meant to reproduce the buffer conditons used 
by Elberry et al [2].  The sample represented by the closed circles was prepared in the 
same equilibration buffer used for purifying Complex III, and is the standard buffer 
used by the Dutton laboratory.  The open circles represent the same protein sample 
with 50 mM histidine added to the redox buffer.   	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c1 midpoint potentials of approximately +50 mV that fall outside of the well-defined 
thermodynamic threshold for heme c1 [5] If their midpoint potentials were correct, 
Complex III would be unable to function because the thermodynamic barrier for FeS 
cluster to heme c1 electron transfer would be insurmountable.  This discrepancy can be 
explained by their use of an imidazole buffer for protein purification and a histidine 
buffer in their redox titration experiments.  As shown in figure 2.5, the presence of 
histidine and/or imidazole can lower midpoint potentials of heme cofactors by over 50 
mV.  Eliminating this artifact from their experiments would raise their reported midpoint 
potential values to lie within the thermodynamic range previously defined for heme c1 
and within the midpoint potentials determined in this chapter. 
2.5  Conclusion 
 The specific engineering element of R. sphaeroides Complex III responsible for 
the robustness of its heme c1 active site must include other interactions beyond those 
provided by residues neighboring the active site, or may not be structurally related to the 
heme c1 active site.  It could be that electrostatic interactions with the FeS cluster (when it 
is rotated proximal to the heme c1 active site) are enough to stabilize the midpoint 
potential of R. sphaeroides heme c1 and preserve turnover of the high potential chain. 
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Chapter 3:  Design and characterization of an 
amphiphilic maquette, AP6 
 
 
 
 
 
The maquette approach uses simplified versions of natural proteins to investigate the 
basic protein engineering necessary to reproduce functional elements of biological energy 
transduction.   The first maquette family, which had a hydrophilic (HP) exterior, 
established the design principles for iron-protoporphyrin IX (FePPIX) binding and 
demonstrated proton coupling to oxidation/reduction.  However, hydrophilic maquettes 
cannot unravel design principles for protein assembly into membranes.  Therefore, a 
second maquette family was designed to be amphiphilic (AP), meaning it contains both 
HP and lipophilic (LP) domains, and can assemble inside membranes.  In this chapter, a 
new member of the AP family of maquettes is fully characterized, AP6.  These 
experiments reveal the full potential of AP6 to serve as a model system for studying 
complicated transmembrane proteins, such as Complex III.  The results contained within 
this chapter are a part of two manuscripts in preparation [7, 8]. 
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3.1 Introduction 
 A century before this thesis work began, Emil Fischer won the Nobel Prize and 
‘foresaw a time in which physiological chemistry will not only make greater use of 
natural enzymes, but will actually resort to creating synthetic ones’ [9, 10]. Fischer’s 
prediction was remarkably astute, as the field of de novo protein design has indeed 
created robust protein-cofactor complexes that serve as simple models (or as the Dutton 
laboratory has named them, maquettes) for much more complicated natural 
oxidoreductases.  Protein designers have established the principles for assembling water-
soluble α-helical bundles [1, 11-16], transmembrane α-helical proteins [2, 17], and basic 
β-sheet proteins [18, 19]; however, translating any particular protein function into a 
successful synthetic protein construction remains challenging.   
 Part of what makes reproducing protein function difficult is an incomplete 
understanding of the mechanisms of complicated oxidoreductases, such as Complex III.  
These proteins have a built-in complexity arising from Darwin’s principle of multiple-
utility [20], which states that each amino acid in a protein is naturally selected for 
multiple and overlapping roles.  Therefore, one of the engineering challenges protein 
designers face is paring down this complexity to focus on one or two functional roles for 
their model system and progressively build up these functions, one amino acid at a time.  
 The design strategy for recreating structure and function in membrane-bound 
synthetic proteins is achieved in three main steps:  1) extract the basic engineering 
requirements from membrane oxidoreductases and reproduce them in hydrophilic (HP) 
maquettes; 2) provide a structural basis for lipophilic (LP) maquette assembly into a 
membrane; and 3) integrate properties from the HP and LP proteins designed in steps one 
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and two into an amphiphilic (AP), transmembrane maquette. This work built upon from 
established maquette families existing in the Dutton laboratory and published from other 
sources to accomplish the third step – applying what has already been learned through HP 
and LP designs towards reproducing transmembrane proton-coupled electron transfer 
function into a simplistic AP maquette design, named AP6.  
  3.1.1 Step 1: reproducing membrane protein function in HP maquettes.   
As outlined in chapter one, the main functional elements of biological energy 
transduction are conversion of light or chemical redox energy into electron transfer, 
coupling electron transfer to proton translocation, and coupling protonmotive forces with 
conformational changes.  As the mechanism of Complex III contains all of these 
functional elements, the first step of protein design was to re-establish the hydrophobic 
di-heme b subunit from Complex III as a HP four-helix maquette [16, 21].  
 Through the binary patterning of polar and non-polar residues, Regan and 
DeGrado were the first to demonstrate that soluble four α-helix bundles could be 
assembled from simple heptad repeat peptides [22].  In their work, polar residues were 
positioned on the protein surface, and non-polar residues were aligned in the core of the 
protein, creating hydrophobic interactions that drove the assembly of the helices into a 
four-helix bundle protein.  This simple design proved to be easily manipulated, creating a 
family of HP maquettes able to bind many different types of cofactors, including hemes 
[1, 3, 5, 16, 21, 23, 24], quinones [25, 26], flavins [27], iron-sulfur clusters [28], redox-
active tyrosine and tryptophan radicals [15, 29, 30], carboyxlate-bridged dimetal clusters 
[31, 32], chlorophylls [33], and chlorins [34, 35].     
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 However, creating a peptide sequence that facilitates cofactor ligation and 
function is not enough to create a successful maquette protein; all successful maquette 
designs also have singular structures.  Though the first HP maquettes relied upon global 
hydrophobic sequestering rather than specific residue-residue contacts, design of native-
like singular structures in maquettes has now been approached by many different 
methods [14, 16, 36-38].  The Dutton laboratory has relied upon iterative design to attain 
successful structural resolution for the HP maquette family.  This design process 
progresses from the assembly of a generic protein helical bundle, to insertion of cofactor 
ligating amino acids, and finally towards iteratively testing and redesigning to engineer 
function and singular structure. 
 As shown in Figure 3.1, Dutton laboratory maquette design began with the design 
of H10H24, which was derived from three and half repeats of the LLKKLLE heptad 
sequence.  A tryptophan residue was incorporated near the N-terminus of the protein on 
the exterior surface to facilitate optical detection using UV-visible spectroscopy methods.  
Cofactor binding in this protein was achieved through replacement of two leucine 
residues (Leu 10 and Leu 24) in the interior of the protein with histidine residues, and N-
terminal disulfide-forming loops (CGGG) were incorporated between sets of helices to 
reduce the possibilities for overall protein assembly to just two conformations – syn (all 
helices parallel) and anti (helices anti-parallel, or facing in opposite directions).  Variants 
of this protein, such as H10A24, were also successfully created and characterized, and 
were found to have allosterically regulated conformational switches (from all-syn to all-
anti) upon redox change of the bound heme cofactors [12]. 
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Figure 3.1: The Dutton laboratory maquette family tree [1-5].  Purple regions 
of the protein cartoons depict the locations of hydrophobic residues, red 
regions correspond to acidic residues, blue regions represent basic residues, 
and yellow regions indicate the placement of amino acids with carboxyamide 
functional groups.   
 
H10H24 
L31M 
HP family 
BT family AP family 
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 This mobility between conformations was eliminated in the apomaquette L31M, 
which incorporated β-branched amino acids in the interior of the protein to solidify a 
singular structure.  L31M was characterized by NMR [4] and by x-ray crystallography  
[37] and then redesigned as HP-1, a disulfide-bridged two-α-helix peptide with two 
histidines for heme ligation [3].  This peptide retained the singular structure of L31, as it 
self-assembled to form an anti four-helix bundle, and also maintained the strong coupling 
between heme redox reactions and glutamate acid-base transitions initially designed in 
H10H24.  
 With a basic heme-binding HP scaffold in place, the HP design evolved through a 
series of iterative modifications to create HP7, an oxygen transport protein with 
properties and function remarkably similar to neuroglobin [1].  Unlike its predecessors 
H10H24 and HP1, HP7 only binds two hemes, with the histidine at residue 24 replaced 
with a phenylalanine.  Another structural difference that is the key to HP7 function is the 
N-terminal loops are linked into a monomeric ‘candelabra’ structure, further constraining 
water access to the heme binding site.  Additionally, the rotation of three glutamate 
residues into the protein core destabilizes one of the iron-histidine ligations, producing a 
population of penta-coordinate heme that is then free to bind exogenous ligands such as 
carbon monoxide or oxygen [1].   
 3.1.2 Step 2: Modifying HP designs to create proteins that can assemble in 
detergent micelles or phospholipid bilayers.  As the HP proteins have been 
progressively designed to shield water from their active site in order to stabilize the 
formation of an oxy-ferrous state, some of the key design strategies employed by the HP 
family of maquettes was applied towards the design of LP and AP maquettes. The same 
 52 
hydrogen bonding pattern in the HP protein core that forms its α-helical secondary 
structure was also used in designs of membrane-associated peptides.   
 Once the secondary structure is formed, it must be inserted into a membrane 
interface.  Hydrogen bonding residues have sufficient thermodynamic driving force for 
membrane helix association [39, 40]; however, the degree of stabilization in the 
membrane is strongly dependent on the position of those residues within the membrane 
interface.  When asparagine is positioned in the middle of a membrane, it has been shown 
to provide more stability than when it is located directly at the membrane-solvent 
interface [41]. Additionally, certain sequence motifs have been demonstrated to aid 
assembly of peptides in membranes.  For example, Lear et al. demonstrated that the 
incorporation of multiple serine residues in specific motifs drives the association of 
simple transmembrane α-helices into higher oligomers that were then functional as ion 
channels [42, 43].  Subsequently, Engelman et al. also confirmed that the incorporation 
of multiple serine and threonine motifs drives transmembrane assembly [44]. 
 The length of the peptide assembling into the membrane can also affect peptide-
lipid interactions [45]; however, hydrophobic mismatch between the membrane interface 
and the peptide can be compensated for in peptide designs.  Charged residues with long 
and/or aromatic side chains (such as lysine or phenylalanine) can overcome hydrophobic 
mismatch by partitioning into the headgroup region of the bilayer [46].  Additionally, 
peptides with larger tilt angles can also accomplish membrane assembly with slightly 
shorter lengths [45]. 
 3.1.3 Step 3: Integrate properties from the HP and LP proteins into an AP 
maquette.  The design and construction of the AP family of maquettes was intended to 
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provide a simplistic platform for achieving functions typically carried out by more 
complicated biological enzymes across a membrane interface.  Three existing AP family 
members were characterized previous to this work – AP1, AP2, and AP3 [2, 17].  AP1 
combined 14 residues from HP1 with 24 residues from the membrane domain of the 
natural M2 channel from the influenza virus through a flexible linking sequence 
(GGNG).  This peptide assembled as a syn four helix bundle, and each assembled 
maquette bound up to two heme cofactors via histidine ligation located in the HP domain.   
Two variants of this maquette, AP2 and AP3, were created to explore heme-binding 
characteristics in the LP domain.   These maquettes removed the heme-ligating histidine 
from the HP domain of AP1, and modeled their LP domain sequences after the 
transmembrane helices found in the b-subunit of Complex III.  These two variants were 
 
Figure 3.2: Polar plot diagram for the AP6 peptide.  There are three histidines in the 
AP6 peptide sequence for heme ligation – histidine 10 (binding site “a”), histidine 21 
(binding site “b”), and histidine 35 (binding site “c”).  AP6 assembles as a four α-
helix bundle in either lipid vesicles (top right) or detergent micelles (bottom right). 
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the first examples of successful cofactor binding sites within a designed peptide that were 
located in a LP domain. 
  Selection of the primary sequence for AP6 was aided in part by what is known 
about previously designed maquettes in the HP [1, 5, 12] and AP families [2, 17].  AP6 
incorporates characteristics of many of its predecessors, as it has a HP-based domain 
taken from HP7 and an LP-based domain built upon those tested in AP2 and AP3.  AP6 
has multiple heme binding sites (one within the HP domain and two within the LP 
domain).  This design, shown in cartoon form in Figure 3.2, was meant to combine the 
best engineering elements learned from previous maquettes to become the first de novo 
designed protein to establish transmembrane electrochemical and proton gradients akin to 
those that occur in more complicated natural systems, such as Complex III. 
3.2 Materials and Methods 
 3.2.1 Peptide synthesis and purification.  Table 3.1 outlines the sequences of 
AP6 and its mutants AP6a, AP6b, AP6c, AP6ab, AP6bc, and AP6ac.  The peptides 
described in Table 3.1 were synthesized on a continuous-flow solid-phase synthesizer 
(CEM) using a standard Fmoc/tBu protection strategy on a Fmoc-PEG-PAL-PS resin 
(NovaBioChem) on a 0.2 mmol scale. The peptides were purified on a reversed-phase 
C18 HPLC column (Vydac) using a 65%-70% gradient of acetonitrile (Fisher) and water 
both containing 0.1% (v/v) trifluoroacetic acid (Sigma). The purity and molecular weight 
of the acetylated peptides were confirmed by matrix-assisted laser desorption/ionization 
mass spectrometry (MALDI-MS), and the molecular weights of the mutant peptides are 
listed in Table 3.1.  Peptide yields were comparable to water-soluble peptides of similar 
length [1].  
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 With the exception of pH dependent experiments, all experiments were performed 
in buffered solutions containing 100 mM potassium chloride and 50 mM potassium 
phosphate (pH 8.0). The word maquette refers to the desired total assembly of four 
peptide helices.  As such, our peptide concentrations reported here are for assembled 
four-helix bundles. Peptide concentrations were determined by UV-visible absorbance 
spectroscopy at 280 nm with an extinction coefficient of 22,400 M-1 cm-1 bundle-1 
 Table 3.1 Summary of the sequences and MW of AP6 and AP6 variants  
 
Protein MW (g/mol) Sequence 
AP6 5022 !"""#$%&'!"###()&&**(*!$"
*$)+*$$,($(,-!%&))*)*"#".
AP6a 5042 !"""#$%&'!"###()&&**(*'$"
*$)+*$$,($(,-'%&))*)*"#".
AP6b 5042 !"""#$%&''"###()&&**(*!$"
*$)+*$$,($(,-'%&))*)*"#".
AP6c 5042 !"""#$%&''"###()&&**(*'$"*
$)+*$$,($(,-!%&))*)*"#".
AP6ab 5032 !"""#$%&'!"###()&&**(*!$"
*$)+*$$,($(,-'%&))*)*"#".
AP6ac 5032 !"""#$%&'!"###()&&**(*'$"
*$)+*$$,($(,-!%&))*)*"#".
AP6bc 5032 !"""#$%&''"###()&&**(*!$"
*$)+*$$,($(,-!%&))*)*"#".
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calculated from the AP6 sequence using the Swiss Institute of Bioinformatics’ EXPASY 
server (http://us.expasy.org/cgi-bin/protparam). 
 3.2.2 Peptide Solubilization. Water-insoluble AP6 peptides and their 
assembled maquettes need a detergent for solubilization in aqueous buffers. We have 
determined that, in general, common detergents near or above the critical micelle 
concentration (CMC) readily solubilize AP6 maquette family members.  In these 
experiments, dodecylphosphocholine (DPC) or Zwittergent was used to solubilize AP6 
at a final concentration of 2 mM.  AP6 can also be incorporated into phospholipids 
vesicles.  Gregory Wiedman and Paul O’Brien pursued this line of solubilization.  
Vesicles were prepared from a 9:1 mixture of 1-palmitoyl-2-oleoylphosphatidylcholine 
(POPC) and 1-palmitoyl-2-oleoylphosphatidylserine (POPS).  The lipid mixture was 
dried under nitrogen gas and then overnight under vacuum.  The dry lipids were co-
dissolved with a solution of AP6 in detergent, and then dialyzed against a buffer solution 
without detergent. 
3.2.3 Heme binding.   A 1 mM stock solution of hemin (Sigma) was prepared in 
20 mM potassium hydroxide and its concentration was verified using a standard 
hemochrome difference spectrum, as described by Berry et al [47]. The aliquot of hemin 
to be added was then determined based upon the concentration of the hemin stock and the 
concentration of the AP6 solution.  Then, the aliquot of hemin was added and stirred for 
one minute, after which complete heme incorporation into AP6 was observed by a 
spectral shift in the heme absorbance from unbound heme (380 nm) to bound, oxidized 
heme (412 nm).  Aliquots were titrated in until the desired amount of heme was 
incorporated into the protein.  
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 Solutions of millimolar zinc porphyrin were made in DMSO, and the exact 
concentration of these solutions was also determined using a reduced – oxidized 
absorbance differences and the extinction coefficient at 412 nm, 22,100 M-1cm-1.  It was 
important when measuring the concentration of the zinc porphryin solution that the stock 
was not too concentrated, as the absorbance of millimolar solutions are difficult to 
measure accurately.  Therefore, though stock solutions for titrations were still millimolar 
in concentration to limit the volume of porphryin added to the AP6 solution, this stock 
was diluted by 10- or 100-fold in order to accurately determine the true concentration. 
 3.2.4 Analytical ultracentrifugation.  A Beckman XLA/I analytical centrifuge 
in the DeGrado laboratory was used to determine the molecular weight of self-assembled 
AP6 complexes with and without hemin bound.  The molecular weight of the complex 
was assessed in a 5 mM DPC solution, and density was matched with D2O (51%) so that 
the contribution of the detergent solution to the buoyant molecular weight of the peptide 
complex would be negligible.  Sedimentation equilibrium experiments in density-
matched D2O solutions were done at 25 °C at four speeds (30,000, 35,000, 40,000, and 
45,000 rpm) and two wavelengths (280 nm and 412 nm).  Data analysis was completed 
using the WatFitter4 program designed by Dr. James Lear in the DeGrado laboratory .   
 3.2.5  Circular dichroism (CD).  Gregory Wiedman measured CD spectra of AP6 
to determine its secondary structure.  The CD trace shown was taken at 15 °C. 
 3.2.6 Oxygen binding determination. Stopped flow analysis of predominantly 
mono-exponential binding kinetics of O2 and CO ligating with ferrous hemin in AP6 
were followed spectroscopically in collaboration with J.L.Ross Anderson according to 
published methods [1].   Rapid stopped-flow mixing of AP6 with CO gas concentrations 
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from 2% to 50% saturation at 15 °C was completed using an Olis RSM 1000 
spectrometer.  Three different solubilization conditions for AP6 were used to determine if 
the detergent/lipid composition had any effect on ligand binding: 2 mM DPC, 2 mM 
Zwittergent, and incorporation into phospholipid vesicles comprised of 2-
oleoylphosphatidylcholine (POPC) and 1-palmitoyl-2-oleoylphosphatidylserine (POPS).  
The Olis machine scans both the α-band and Soret band absorptions 1,000 times per 
second, which was then followed by SVD analysis of the kinetic components at each 
wavelength.  
3.2.7 Midpoint potential determination. Equilibrium redox potentiometry was 
used as a functional analysis of the oxidation and reduction of hemes bound to AP6 [48].  
Redox titrations were performed in an anaerobic 1 mL cuvette (Starna Cells) equipped 
with a silver / silver chloride and platinum combination electrode (Microelectrodes Inc.). 
All of the potentials reported are in reference to the normal hydrogen electrode (NHE).  
The reduction potential of the cuvette solution was adjusted by adding 1 µL aliquots of 
freshly prepared solutions of either sodium dithionite (for reducing) or potassium 
ferricyanide (for oxidizing). 20 µL of a stock solution containing the following redox 
mediator dyes was also added to the solution (final concentrations reported): 5 μM 1,2-
naphthoquinone, 5 μM 1,4- naphthoquinone, 20 μM duroquinone, 10 μM pyocyanine, 5 
μM indigotrisulfonate, 10 μM 2-hydroxy-1,4-naphthoquinone, 1 μM indigocarmine, 10 
μM anthraquinone-2-sulfonate, and 5 μM benzyl viologen. After equilibration at each 
midpoint potential, the UV-visible spectrum of the AP6-heme complex was recorded, 
monitoring in particular the increase in the sharp α-band absorption at 559 nm relative to 
a 575 nm reference wavelength. 
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3.3 Results 
   3.3.1 AP6 assembly.  The molecular weight of the AP6 complex in DPC was 
determined by analytical ultracentrifugation.  The absorbance vs. radius data collected for 
each sample was fit using the WatFitter4 program to determine the experimental 
molecular weight for each sample. The aggregation number of AP6 was calculated by 
dividing this experimental molecular weight by the molecular weight of a single AP6 
peptide.  In experiments where hemes were added, the aggregation number was 
determined by the following formula: 
  N = (MW – 652m) / 5022                                    Equation 3.1 
where m is the number of hemes added per tetramer. The aggregation number for both 
the apo and holo forms of AP6 was 4, indicating that AP6 assembles cleanly in micelles 
as a tetramer.  Experiments completed by Paul O’Brien and Gregory Wiedman also 
confirmed tetrameric assembly of AP6 in lipid vesicles [8].     
 As shown in Figure 3.3, the weight fraction of over a range of concentrations 
indicates that apo-AP6 assembles predominantly as a tetramer at millimolar 
concentrations, but the population of AP6 is split between half monomer and half dimer 
at micromolar concentrations of apo protein.  Upon the addition of a heme, all other 
species are eliminated, and AP6 assembles entirely as a tetramer.  This suggests that 
heme binding stabilizes the assembly of the four helix bundle.   
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Figure 3.3: Analytical ultracentrifugation data for AP6 in its apo (left) and holo (right) 
forms.  Shown in top panels are the absorbances at 280 nm at different radii from the 
center of the ultracentrifugation cell.  Each trace represents a different speed: 40,000 
rpm (red), 45,000 rpm (green), and 50,000 rpm (blue).  This data was fit using the 
WatFitter4 program to obtain the MW of the AP6 complex.  The bottom panels depict 
the weight fraction analysis of AP6 samples. AP6 assembles as a tetramer (blue trace) 
at millimolar concentrations without heme, and its assembly is aided by adding heme 
equivalents.  With one heme equivalent bound, AP6 is solely a tetramer even at 
nanomolar concentrations. 
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 Though analytical ultracentrifugation experiments verified the tetrameric 
assembly of AP6, circular dichroism (CD) confirmed the secondary structure of the AP6 
design to be comprised of stable alpha helices (Figure 3.4).  The alpha-helical content of 
a protein can be calculated by the following equation: 
  % a-helix  = ([θ]222 nm-θC) / (θH - θC)                            Equation 3.2 
where θ222nm is the molar ellipticity at 222 nm, θH and θC are the baseline ellipticities for 
the helix and random coil respectively.  Using the empirical values of Rohl and Baldwin 
[49]: 
θH = 2220 – 53T                                             Equation 3.3 
 
Figure 3.4 A CD spectrum of 4 µM AP6 at 15 °C (data collected by Gregory 
Wiedman). Secondary structure can be determined by CD spectroscopy in the far-UV 
spectral region (190-250 nm), and AP6 displays spectral properties characteristic of a 
helical structure.  Helical content can be calculated using the molar ellipticity of AP6 
at 222 nm, and from these calculations, AP6 is 92% helical. 
 
!"" !!# !#" !$# %""
&!"
&'"
"
'"
!"
%"
("
M
ol
ar
 e
lli
pt
ic
ity
Wavelength, nm
 62 
θC=(-44000 + 250T)(1-3/Nr)                                   Equation 3.4 
where T is temperature (in ºC) and Nr is the number of amino acid residues, tetrameric 
AP6 is 92% helical at 15 ºC. 
 3.3.2 Heme binding in AP6.  AP6 was designed to bind up to six bis-histidine 
ligated porphryns.  The binding site ligated to histidine 10 in the HP region is referred to 
the “a” binding site, whereas the two sites located in the LP region at histidines 24 and 35 
are named “b” and “c” respectively.  Figure 3.5 shows a hemin titration of 2 µM AP6 in 2 
mM DPC.  The Soret absorbance of heme increases linearly with heme additions until 
one heme per bundle is bound.  This indicates that the first dissociation constant (Kd1) is 
below the 5 nM resolution level of this experimental assay.  The linear relationship 
between the initial points can be used to estimate the extinction coefficient of the bound 
heme, which reduces the number of unknowns in the Mathematica (Wolfram Research)   
program used for fitting the heme titration data to heme dissociation constants.  The AP6 
binding data shown in Figure 3.5 were fit to six independent binding sites with 
equilibrium binding constants of Kd1 < 5 nM, Kd2 = 70 nM, Kd3 = 1.4 µM Kd4 = 2.1 µM, 
Kd5, Kd6 > 5 µM in 2 mM DPC.  AP6 variants were fit to binding constants based upon 
the number of available hisitidine binding sites.  All of the Kd values for AP6 proteins are 
listed in Table 3.2. 
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Figure 3.5: Heme binding to a) 1.53 µM AP6 in 2 mM DPC b) 2 µM AP6 in DCM, 
and c) 1 µM AP6 in POPC vesicles (completed by Gregory Wiedman).  The curve in 
a) can be fit to six different binding constants, representing all six binding sites found 
in AP6.  Those constants are: Kd1 < 5nM, Kd2 = 70 nM, Kd3 = 1.4 µM, Kd4 = 2.1µM, Kd5, 
Kd6 > 5 µM.  
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 Binding porphyrins that contain zinc is advantageous because these porphyrins 
are then photoactivatable, allowing for the investigation of light-initiated electron- and 
energy-transfer events between chromophores in multi-cofactor maquettes. Initial 
ZnPPIX binding titrations were completed using AP6 solubilized in 2 mM DPC.  
Previous maquette designs have demonstrated single-histidine axial ligation of ZnPPIX 
[50],  and fully assembled AP6 also adopts this coordination upon cofactor binding.  As 
shown by the initial linear dependence of bound heme absorbance to heme:bundle in 
Figure 3.6, AP6 is able to bind up to seven ZnPPIX cofactors at nanomolar affinity 
before the cofactor binding strength weakens.  
Table 3.2: Summary of Kd values for hemes bound to AP6 and AP6 variants 
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 3.3.3 Redox potentials of hemes bound to AP6.  Figure 3.7 illustrates redox 
titrations of AP6 with varying equivalents of heme bound.  The titrations reveal a 
splitting in redox potential that originates from a difference in heme environment due to 
 
Figure 3.6  Titrations of a millimolar ZnPPX solution (in DMSO) added to 1 µM AP6 
in 2 mM DPC (data obtained by Gregory Wiedman). 
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Figure 3.7  Redox titration of 4 µM AP6 in 2 mM DPC with two heme equivalents 
added. 
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heme-heme charge interactions.  The relationship between midpoint potential and pH was 
explored for the hemes bound to AP6 and is shown in Figure 3.8.   The higher potential 
heme had a pKox of 6.1 and a pKred of 8.3.  Over a modest pH range from pH 6.1 to pH 
8.3, the slope was -57 mV/pH unit, indicative of a 1 e- / 1H+ relationship.  The low 
potential heme displayed a pKox of 7.2 and a pKred of 8.8.  Interestingly, between those 
pH ranges, this heme did not display the same 1 e- / 1H+ relationship shown for the higher 
potential heme, but instead had a slope of -37 mV/pH unit.   
 3.3.4 Generation of the oxy-ferrous state in AP6.  AP6 with reduced hemes 
bound was tested to see if the hemes could ligate CO or O2.  It was expected that since 
 
Figure 3.8 Determination of the pKred and pKox for each of the AP6 heme b midpoint 
potentials.  Data was fit to Equation 3.7. 
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the HP domain of AP6 was based on the successful oxygen-binding HP7 protein [1], any 
reduced hemes bound to this domain should also be able to ligate oxygen.  Surprisingly, 
AP6 only bound oxygen when solubilized in Zwittergent; DPC and phospholipid vesicles 
were not successful environments for AP6-heme oxygen binding.   
 Figure 3.8 (a) and (b) depict the stopped-flow spectral changes for mixing 
 
Figure 3.9: Forming the oxy-ferrous intermediate in 5 µM AP6 in 2 mM Zwittergent.  
Panels a (Soret) and b (a-bands) depict the spectral changes associated with oxidized 
(green), reduced (blue), and oxy-ferrous generation (red).  Panels (c) and (d) reflect 
the auto-oxidation rate of heme b from the oxy-ferrous state (Fe2+-O2) to the oxidized 
form (Fe3+).  These experiments were completed in collaboration with J.L. Ross 
Anderson. 
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reduced AP6 proteins with oxygen at 15 º C. The Soret (a) and α-band (b) spectra show 
the transformation of the reduced heme b (blue) to the oxy-ferrous state (red), which 
eventually becomes oxidized (green).  Intermediate states are shown in gray.  The auto-
oxidation rates from an AP6 oxy-ferrous state (Fe2+-O2) to its oxidized state (Fe3+) were 
measured with 1 (c) and 2 (d) hemes bound.   
 3.3.5 AP6 variants.  Six variants of AP6 were created using solid phase peptide 
synthesis to learn more about the individual characteristics of each heme binding site.  
The heme binding properties of these mutants – AP6a, AP6b, AP6c, AP6ab, AP6ac, and 
AP6bc – are listed in Table 3.2.  The names of these mutants correspond with the binding 
sites present as labeled in Figure 3.2; for example, AP6a retains the histidine at residue 
 
Figure 3.10 Heme titration with 1.25 µM AP6ab.  Though it has four binding sites 
available, this AP6 variant very clearly binds only two tightly from the break in the 
linear binding relationship that occurs after 2 hemes per bundle were added to the 
solution.  Kd values were determined to be Kd1 < 5 nM and Kd2 = 120 nM. 
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10, but not at residues 24 and 35, where phenylalanine was substituted.   
 The variants were first analyzed by analytical ultracentrifugation to determine if 
all of the heme binding sites were required for tetrameric assembly of AP6.  AP6 does 
not require all three heme binding sites to be present for tetrameric assembly.  All of the 
AP6 variant proteins containing single or multiple binding sites assembled as tetramers 
except AP6c, which aggregated as an octomer in both its apo- and holo-forms.   
 The heme binding characteristics of the AP6 variants varied considerably from 
the binding patterns associated with AP6, and are outlined in Table 3.2.  Though the 
mutants with a single heme binding site (AP6a and AP6b; AP6c was not tested since it 
did not assemble as a four-helix bundle) both bound up to two hemes tightly, the mutants 
that contained four heme binding sites (APab, APac, APbc) did not all bind up to four 
hemes. AP6ab bound two hemes that were fit to binding constants around the nanomolar 
constraint of the assay (Figure 4.10).  AP6bc bound hemes weakly, with much of the 
heme equivalents added remaining unbound.  
3.4 Discussion 
 3.4.1 Design characteristics. The main principle of AP6 construction was the 
same structured assembly driven by Regan and DeGrado [22] and its AP predecessors [2, 
17] – a  well-developed exterior pattern of polar and non-polar residues exposed along 
the axis of the four-helix bundle.  However, it was important that these external 
interactions did not conflict with the interior amino acids that make up the helix interface.  
Additionally, a reasonably accurate prediction of the location of each residue was needed 
to ensure that the metal porphyrin-ligating histidine residues within the interior were 
properly aligned to ensure tight cofactor binding.  The HP and LP domains each have 
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their own amphiphilic exterior and interior patterns and specific interior residues that 
need to be aligned with respect to one another in one helix.  As shown in Figure 3.2, the 
alignment of the two domains within the AP6 sequence was accomplished by plotting the 
sequence on polar graphs that emphasize the angular position of each residue in the 
sequence according to the following equation: 
     θ = 360° / r                                       Equation 3.6 
where r is the number of residues per turn.  Since the value of r cannot be determined 
without structural characterization, polar plots were created using an r-value assumed 
from the related protein structure of HP7 (3.58 residues per turn) and assuming an ideal, 
straight a-helix with 3.6 residues per turn for the transmembrane portion, or a θ= 100°. 
 The sequence of the HP domain found in AP6 is 15 residues in length and 
incorporates the bis-histidine ligating sequence from HP7 that was successful for tight 
cofactor binding.  The LP domain is based on the native hydrophobic heme binding 
sequences from Complex III [6].  Complex III enzymes contain a conserved four-helix 
bundle that ligates bL and bH between four histidine residues on helices b and d.  As 
shown in Figure 3.11, unlike the structure surrounding the bL site, where the diameter of 
the four-helix bundle increases around the heme binding site to allow for interactions 
with additional helical segments, the helical structure around the heme bH binding site 
(residues 188-200) is a more ideal alpha helix.  In the AP(2-3) designs, Complex III 
residues 188-200 around the heme bH binding site served as a template for their LP 
domain.  The new AP6 design extends the sequence of the LP domain to 29 residues, but 
does still maintain high homology with the sequence found in Complex III.  In addition, a 
four residue helix-capping sequence, GEGL, was used at the C-terminus to promote 
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hydrogen bonding interactions that can be lost at the end of a peptide sequence.  One 
factor that simplified the AP6 design was that the tilt angle of the HP7 helix (5.1°) 
closely matches the tilt angle calculated for Complex III (8.5°); therefore, the flexible 
linking sequence found in the earlier AP1 design was not necessary in this design to link 
the two domains.   However, two phenylalanine residues were placed between the HP and 
LP domains, because phenylalanine can successfully partition between polar and non-
polar interfaces due to its aromatic character. 
 3.4.2 AP6 may require additional structural constraints.  Though the 
structure of AP6 is not yet known on a molecular scale, much is still known about AP6 
Figure 3.11 Crystal structures of native Complex III depicting its b subunit in blue 
(left) and zoomed in (right).  Shown in yellow are residues 188 – 200, where the 
Complex III helix is the most ideal.  The LP domain found in AP6 is based upon this 
section of Complex III.  This figure was drawn from PDB file 1BE3 [6] using Pymol 
(DeLano Scientific and Schröedinger) software.   
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secondary structure and assembly.  CD experiments reveal that AP6 is highly helical in 
nature, and that its helical structure is stable over a wide range of temperatures and 
denaturant concentrations [8]. High stability in the LP domain was expected for AP6 (as 
was demonstrated by predecessor AP family members [2]) because disrupting hydrogen 
bonds of alpha helices in a hydrophobic environment is energetically unfavorable.  Not 
surprisingly, the helical nature of the HP domain has been demonstrated in earlier HP 
proteins [51], and is most likely further stabilized in AP6 by the LP domain. 
 AP6 assembles as a tetramer in its apo-form, and binding hemes stabilizes four-
helix bundle formation at higher concentrations.  AP6 variants that lack one or more of 
the three histidine binding residues are not able to maintain heme binding at all remaining 
available sites in some cases.  These results suggest that without all of the porphryn 
coordinating histidines present in its sequence, AP6 may adopt different conformations 
that do not promote heme binding, even though it is still assembled as a tetramer.  Also, 
removing the tightest binding site “a” in AP6bc may interrupt cooperative heme binding, 
lowering the binding affinity for the “b” and “c” sites such that they no longer bind 
hemes as tightly.  
 3.4.3 Heme properties in AP6.  The observation of redox potential splitting 
upon addition of just one heme cofactor demonstrates cooperative cofactor binding.  In 
this scenario, binding one heme in one binding site increases the affinity for the other 
heme to bind in a binding site within the same maquette.  When one heme is added, the 
redox titrations are measuring the redox potential of a heterogeneous mixture of AP6 
maquettes, where the half of the maquette population is comprised of apo-proteins and 
half of the AP6 proteins have two heme equivalents bound.  Therefore, the best 
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experimental conditions for redox titrations are to bind at least two hemes so that the 
maquette population is homogenous.   
 The assembly topology of the maquette dictates the heme-heme distances, and 
therefore heme-heme charge interactions, in maquettes with at least two hemes bound [2, 
12].  AP6, like many previous maquette designs [1, 2, 5, 12, 17], assembles with a syn 
topology (Figure 3.2).  Maquettes with a syn topology, such as AP1 [2], H10A24 [5, 12], 
or AP6, ligate two hemes in close proximity, leading to an electrostatic interaction 
between the two cofactors.  In AP6, a single midpoint potential value for that binding site 
is split by ~75 mV when two hemes are added.  This dramatic potential split is consistent 
with an electric field effect – the heme with the -156 mV potential is titrated while 
influenced by the electric field of an uncharged ferrous heme,  while the heme with the -
78 mV potential was titrated while in the presence of the electric field from the other 
charged ferric heme.  
 The redox splitting information can be used to assign cofactor binding constants 
to specific binding sites.  In order for the hemes to have charge-charge interactions, the 
hemes need to be in close proximity to one another.  Therefore, the first two hemes 
equivalents added need to either be bound to two identical binding sites (i.e. both hemes 
bound at this bis-histidine 10 site) or in two sites directly adjacent to one another (i.e. one 
heme bound at the histitine 10 site and one heme bound at the histidine 24 site).  The 
large splitting of ~75 mV in midpoint potential represents the same field strength and 
charge-charge interaction energy observed in the H10A24 maquette [12], suggesting that 
the interaction is derived from two hemes parallel to one another in identical binding sites 
as they are in H10A24.  As AP6a binds hemes more tightly than the other AP6 variants 
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(Table 3.2), it is likely that the first two hemes in AP6 bind to the two binding sites at 
histidine 10 before binding to the membrane-associated sites.   
 Successful formation of an AP6 oxy-ferrous state confirmed that construction and 
assembly of AP6 maintains the symmetric rotation of key glutamate residues into the 
maquette interior required in HP maquettes for oxygen binding, excluding water from the 
redox active site.  However, this occurs only in certain membrane interfaces.  The heme 
binding affinity must change when AP6 assembles in different membrane interfaces, as it 
is the affinity of the heme that drives the rotation of the glutamates into the bundle 
interior and weakens one of the histidine ligands enough to promote oxygen ligation [1].  
Therefore, AP6 assembly varies when solubilized in different detergents (and lipid 
compositions, though that was not explored in this thesis work). 
 3.4.4 Proton coupling to heme midpoint potential.   Proton coupling to heme 
oxidation and reduction requires that the pK value of an acidic or basic group on the 
cofactor (or on a residue within the active site) shifts according to this thermodynamic 
scheme: 
 
 
 
 
 
Scheme 3.1 
Oxidizing the cofactor increased its positive charge, decreasing the proton affinity (pKox) 
of the acidic/basic group.  Likewise, under reduced conditions, the proton affinity (pKred) 
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is increased as the cofactor increases its negative charge.  In regions between the pKox 
and pKred, the midpoint potential of the cofactor will depend upon the protonation state of 
the acidic/basic group, decreasing as the pH increases.  For every proton coupled to one 
electron from a cofactor, the slope of its pH dependence will be -59 mV.  These 
conditions were evaluated for AP6 to determine the pKox and pKred for each of the hemes 
bound.  The heme oxidation / reduction when coupled to protonatable residues is 
described according to the following equation: 
 
 
Equation 3.7 
where E0 is the midpoint potential of the heme at low pH when all of the influencing 
residues are protonated.   
 As shown in Figure 3.8, the high potential heme is dependent on a single proton 
group, as its slope between its pKox and pKa red is -57 mV/pH unit, which is very close 
to the ideal slope of -59 mV / pH for a 1 e- / 1 H+ process.  The proton coupled to this 
midpoint potential could either be associated with either of its bis-histidine ligands, or 
glutamate residue 11, which is located within the heme binding site between the bundle’s 
interior and exterior.  There is some precedent for proton coupling with a glutamate 
residue for hemes bound to AP maquettes; glutamate residues in AP1 were found to raise 
the pKred above pH 8 in its ferrous state [2].  The lower potential heme displays a modest 
proton dependence of -37 mV / pH unit between its pKox and pKred.  This reflects more 
than a full proton equivalent coupled to a single electron transfer, and could mean that the 
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charge-charge interaction between the two hemes also affects its coupling to glutamate 
proton exchange.  
3.5 Conclusion 
 In this chapter, the maquette approach was applied to design a new member of the 
AP maquette family, AP6.   AP6 contains both a HP and a LP domain and assembles as 
tetrameric α-helical bundles in detergents, organic solvents, or in lipid vesicles.  Six  
FePPIX binding sites are distributed within the AP6 sequence to create a transmembrane 
cofactor chain, with two hemes binding in the HP domain (histidine 10), two hemes 
binding at the solvent/membrane interface (histidine 21), and two hemes binding within 
the LP domain (histidine 35).    The hydrophobic environment of the membrane increases 
the redox potential of the bis-histidine bound hemes (in comparison to hemes bound to 
the HP maquettes) and AP6 can withstand significant electrostatic interactions between 
two bound heme cofactors.  Furthermore, AP6 has proton coupling to heme 
oxidation/reduction over a modest pH range.   
 However common it might be for the Complexes within the mitochondrial 
respiratory chain, complexity is not an essential requirement for enzymatic activity.  This 
simple AP6 design was created as a model system for studying the basic functions carried 
out by the enzymes of the respiratory chain, such as Complex III: transmembrane 
electron transfer, electron transfer with aqueous proteins, and proton-coupled electron 
transfer.  In chapter four, the extent of AP6 quinol-cytochrome c oxidoreductase activity 
will be tested using standard Complex III steady-state activity assays. 
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Chapter 4: Demonstrating quinol-cytochrome c 
oxidoreductase kinetic activity by AP6 
 
 
 
 
 
Given its sequence and heme binding capabilities, the AP6 design outlined in chapter 
three could accomplish a variety of potential functions, including: transmembrane 
electron transfer, electron transfer with aqueous proteins, and/or proton-coupled electron 
transfer.  In this chapter, AP6 is tested as a potential quinol-cytochrome c oxidoreductase 
(Complex III) enzyme.  As determined using standard Complex III activity assays, AP6 
is the first example of a synthetic maquette with enzymatic activity within two orders of 
magnitude of a natural protein.  AP6 quinol-cytochrome c oxidoreductase activity can be 
generated with a variety of reduced quinone substrates, and is dependent on the 
concentration of cytochrome c present.  With no obvious quinone-binding site included in 
our protein design, AP6 provides clear evidence that an elaborate quinone-binding site 
within a membrane protein is not essential for generating significant quinol-cytochrome c 
oxidoreductase enzymatic activity from a heme protein.  A version of the work in this 
chapter is in preparation for submission to Biochemistry [1]. 
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4.1 Introduction 
  As outlined in chapters one and two, diffusible redox cofactors that link together 
multiple protein complexes are critical to the design of Complex III. Catalytic sites for 
oxidation and reduction of otherwise stable substrates, including quinone molecules 
together with chains of redox cofactors, add speed and direction to electron transfer and 
proton translocation to turn the free energy of oxidation-reduction reactions into a 
transmembrane ΔµH+.  These electron transfer reactions have been studied extensively; 
however, an understanding of energy coupling as it relates to specific electron transfer 
mechanisms within Complex III remains elusive.  In order to address this problem, a 
basic understanding of the structure, specificity, and functionality of membrane proteins 
needs to be achieved.  In chapter four, the maquette approach [2, 3] was applied to 
engineer a simple transmembrane protein, AP6, to perform the same types of electron 
transfer mechanisms found in more complicated protein systems.  AP6 was engineered to 
contain all of the benefits of a transmembrane cofactor chain capable of accelerating 
electron and proton transfer without the structural or functional complexities that plague 
our understanding of natural Complex III.   
 Complex III is a complicated redox enzyme with many aspects of its mechanism 
undefined, but reproducing its quinol-oxidoreductase function should not be out of reach 
for a transmembrane maquette protein.  Quinones are present in high cellular 
concentrations (millimolar) and are also extremely mobile and reactive [4].  Even without 
specific binding pockets for decylubiquinone explicitly designed, the hydrophobicity of 
the quinone molecules coupled with excess concentrations in the cuvette works to 
promote quinone association with the detergent micelle and hydrophobic AP6 maquette.   
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  Though no other protein has ever been specifically designed to mimic Complex III 
activity specifically, AP6 is not the first example of a maquette protein designed for 
catalysis.  In 2004, Kaplan and DeGrado designed di-iron oxidoreductase mimics that 
catalyzed the two-electron oxidation of 4-aminophenol (kcat / Km = 1500 M-1s-1) to the 
corresponding quinone monoamine using a bound diiron cofactor [5].  The sequence of 
this non-natural enzyme was designed using a computational method that considered 
stabilizing known structural properties of previously designed dueferri (DF) family of 
proteins, as well as destabilizing likely alternative protein folds.  The catalytic efficiency 
of this protein was sensitive to the size of the methyl group in the active site of the 
protein, suggesting that the active site design was specifically engineered to maximize 
catalysis.  Addtionally, de novo designed retro-adolase enzymes were created using 
computational and directed evolution enzyme design strategies [6].  Recently, 
Röthlisberger et al. applied those same techniques to create enzymes that catalyze the 
Kemp elimination reaction, a model reaction for proton transfer from carbon, with 
multiple turnovers on a seconds timescale [7].  Although the turnover rates for these 
enzymes are lower than the rates of many natural proteins, all of these enzymes 
successfully applied known structures towards the design of natural function and 
signified the advancement of the protein design field.  However, one plausible reason for 
their lowered turnover rates could be that these proteins were designed to recreate a 
singular structure of the active natural enzyme, ignoring any transition states that may be 
required to fully reproduce the enzyme’s function.  Therefore, one of the benefits of the 
AP6 design is that its assembly and structure is controlled but not static, allowing for 
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subtle structural movements that would be required for substrate interactions and 
subsequent electron transfer reactions. 
4.2 Materials and methods 
 4.2.1 Complex III growth and purification.  Growth of the R. sphaeroides 
strains was done as described in chapter two [8].  Chromatophore membranes and 
purified Complex III were isolated and purified as described using a DEAE-sepharose 
column (Amersham Pharmacia) [9, 10]. 
4.2.2. Peptide synthesis and purification.  The peptide sequence of AP6 is: 
CGGGEIWKQHEEALKKFFAFHFILPFIIMAIAMAHLLFLFGEGL.  AP6 peptides 
were synthesized on a continuous-flow solid-phase synthesizer (CEM) using a standard 
Fmoc/tBu protection strategy on a Fmoc-PEG-PAL-PS resin (NovaBioChem) at 0.2 
mmol scale. The peptides were purified on a reversed-phase C18 HPLC column (Vydac) 
using gradients of acetonitrile (Fisher) and water both containing 0.1% (v/v) 
trifluoroacetic acid (Sigma). The purity and molecular weight of the acetylated AP6 
peptide was confirmed by matrix-assisted laser desorption/ionization mass spectrometry 
(MALDI-MS) to be 5022 g/mol.  The peptides were purified without difficulty with 
yields comparable to water-soluble peptides of similar length [2, 11].  
 Unless noted otherwise, all experiments were performed in buffered solutions 
containing 100 mM potassium chloride and 50 mM potassium phosphate (pH 8.0). As 
shown previously [12], the maquettes reported here assemble as tetramers; therefore, the 
word maquette refers to the total assembly of four peptide helices.  As such, our peptide 
concentrations reported here are for assembled four-helix bundles. Peptide concentrations 
were determined by UV-visible absorbance spectroscopy at 280 nm assuming an 
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extinction coefficient of 22400 M-1 cm-1 bundle-1 calculated from the AP6 sequence using 
the Swiss Institute of Bioinformatics’ EXPASY server (http://us.expasy.org/cgi-
bin/protparam).  
 4.2.3 Peptide solubilization. Water-insoluble AP6 peptides and their assembled 
maquettes need a detergent for solubilization in aqueous buffers. We have determined 
that, in general, common detergents near or above the critical micelle concentration 
(CMC) readily solubilize AP6 maquette family members [3, 12].  In these experiments, 
we used dodecylphosphocholine (DPC) at a final concentration of 2 mM to solubilize 
AP6. 
 4.2.4 Heme binding.   A 1 mM stock solution of hemin (Sigma) was prepared in 
20 mM potassium hydroxide and its concentration was verified using a standard 
hemochrome difference spectrum, as described by Berry et al [13].  Though AP6 has 
been shown previously to bind up to six hemes [12], in these experiments we chose to 
bind four hemes, as the last two hemes were determined in chapter three to bind with  
micromolar rather than nanomolar affinity.  A 4:1 ratio of hemin to protein was added 
and stirred for one minute, after which complete heme incorporation into AP6 was 
observed by a spectral shift in the heme absorbance from unbound heme (380 nm) to 
bound, oxidized heme (412 nm).   
 4.2.5 Reduction of decylubiquinone (DBH) substrate. Quinols were prepared 
from the oxidized quinone using the method described by Peter Rich [14] and detailed in  
chapter two.  0.25 g decylubiquinone was dissolved in 50 mL diethyl ether and placed in 
a separatory funnel. A solution of 1 g sodium dithionite in 50 mL water was added and 
the mixture was shaken together. The quinone could be seen to initially increase in 
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yellow color due to semiquinone formation, but eventually became colorless as full 
reduction to quinol occurred. The aqueous layer was removed, but the ethereal layer was 
shaken with a second 50 mL solution of sodium dithionite to ensure completion of the 
reduction reaction. After removal of the dithionite solution, the ethereal layer was washed 
twice with a saturated sodium chloride solution. The ethereal layer containing quinol was 
then passed through 30 g anhydrous sodium sulfate in a sintered glass funnel to remove 
any residual water, and the ethereal solution was then dried down by rotovaporization at 
25°C.  The resulting white powder was dissolved in an acidic ethanol solution (95% 
ethanol containing 10 mM hydrochloric acid) and flash frozen in 500 µL aliquots.  
 4.2.6 Enzyme steady state activity measurements. Maquette functionality as a 
quinol-cytochrome c oxidoreductase was measured via its reduction of cytochrome c in 
the presence of excess decylubiquinol [15].  A solution of 25 µM horse heart cytochrome 
c (Sigma) in redox buffer (50 mM potassium phosphate and 100 mM potassium chloride 
at pH 8) and 10 µM decylubiquinone (DBH) was incubated anaerobically in a 3 mL 
cuvette and stirred for one minute, after which a maquette protein was introduced into the 
cuvette in nanomolar concentrations (10-100 nM). Using an extinction coefficient of 18.5 
mM-1cm-1 for the 551 nm – 540 nm difference absorption, cytochrome c reduction was 
monitored over time until the amount of cytochrome c reduced reached a constant 
maximum.   
This cuvette assay was modified for anaerobic stopped flow experiments to obtain 
the initial velocity for AP6 activity.  An Olis multiwavelength stopped flow spectrometer 
was used to measure cytochrome c reduction over 200 s.  100 µL from a syringe 
containing 20 mM decylubiquinone in reaction buffer and DMSO was mixed with 100 
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µL from a syringe containing 25 nM AP6 and 50 µM cytochrome c.   
 4.2.7 Computational work. As described in the Appendix, the Dutton 
laboratory has developed an electron transfer rate expression that offers a simple way to 
examine parameters that directly relate to the oxidoreductase activity of a particular 
mitochondrial enzyme.  The electron tunneling rates of the decylubiquinone, AP6, and 
cytochrome c redox centers were simulated using Equation A.1 in user-written programs 
constructed in Mathematica (Wolfram Research) to create a model for quinone 
semiquinone stability and electron transfer distances [16, 17].     
4.3 Results 
 The maquette approach enables the construction of useful synthetic proteins with 
applications in the material science and medical fields.  This approach has been so 
successful because only the basic protein engineering requirements needed to obtain 
enzymatic activity are applied to the designs, which have so far proven to be relatively 
simple.  To design AP6 to have quinol-cytochrome c oxidoreductase activity, the main 
elements of these electron transfer reactions in Complex III were extracted and 
incorporated into AP6: simple α-helical structure to promote membrane association, both 
hydrophilic and hydrophobic sections of amino acids to promote interactions with both 
the membrane and soluble molecules, multiple histidine sites for heme ligation, and a 
tryptophan molecule for convenience when determining AP6 concentration.   
 4.3.1 Quinol-cytochrome c oxidoreductase activity of AP6.  We 
demonstrated quinol-cytochrome c oxidoreductase activity in AP6 using a steady-state 
turnover assay previously designed to determine Complex III activity (Figure 4.1) [15].  
In this assay, a pool of reduced quinone reduces the hemes in the transmembrane protein, 
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transferring electrons across the membrane interface (Figure 4.1).  The reduced protein 
can then transfer electrons to the oxidized cytochrome c inside the soluble portion of the 
detergent micelle.  The transition from oxidized to reduced cytochrome c is monitored in 
this assay, with activity traces reflecting the total amount of cytochrome c reduced over 
time.   
 
Figure 4.1: Cartoon representations of the components of the assay.  Reduced 
quinol molecules diffuse within reasonable electron transfer distances of both AP6 
hemes and cytochrome c, though reactions with AP6 occur on a much faster 
timescale than those with cytochrome c (background rate).  The two electron 
reduction of AP6 results in two, one electron reductions of cytochrome c 
molecules. 
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 As shown in Figure 4.2, decylubiquinone is significantly reactive with 
cytochrome c even without the aid of a catalytic protein, such as Complex III.  We left 
the background rate in the initial time points visible in this figure so that any changes 
induced by protein additions would be more evident; however, this rate was subtracted 
from the data to determine the true rate of cytochrome c reduction caused by the addition 
of AP6.  The rate of cytochrome c reduction is unchanged when apo-AP6 is added; 
 
Figure 4.2:  Demonstration of quinol / cytochrome c oxidoreductase activity for AP6 
in a standard Complex III activity assay, which monitors the reduction of cytochrome 
c (as indicated by a difference in it 550-540 nm abosrabnce) over the time after AP6 
is added.  In the presence of 10 µM reduced DBH,  50 nM AP6 (green) reduces 25 
µM cytochrome c in a 2 mM DPC detergent solution over two orders of magnitude 
better than free hemin (red), or the background rate when apo-AP6 is present (blue).  
The rate of AP6 reduction is approximately 100 fold slower than Complex III 
(black). 
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adding hemin alone only stimulates this background rate slightly.  However, upon the 
addition of AP6 with just two heme equivalents bound, cytochrome c reduction takes off, 
occurring at a rate ~500-fold faster than the background rate and within 100-fold of the 
rate of R. capsulatus Complex III. Though the design of AP6 supports up to six hemes 
bound per maquette bundle, only two hemes are needed to achieve this maximal 
enzymatic activity (Figure 4.3).  
 In complementary stopped-flow experiments, the cytochrome c substrate 
concentration is varied to resolve kinetic parameters for the various proteins tested in this 
assay (Table 4.1, Figure 4.4).  As expected, AP6 activity increased with increasing 
amounts of cytochrome c, reaching a maximal activity of 62 nM / s.  The Km for 
 
Figure 4.3:  Rates of cytochrome c reduction of 10 nM AP6 with varying ratios of 
hemes bound per bundle as reported by stopped flow data with 25 µM cytochrome c 
and 10 µM DBH present.   
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cytochrome c association with AP6 was 14.5 µM, which is almost identical to the Km for 
cytochrome c with Complex III of 13.4 µM [18].  In contrast, the concentration of 
decylubiquinone in these assays does not have any affect on AP6 activity once the 
background rate is accounted for because quinone levels are already saturating in this 
assay.   
 4.3.2 Testing AP6 activity with alternative quinone substrates Successful 
reduction of AP6 by a quinone pool is not specific to an excess of ubiquinone present; 
 
Figure 4.4: Solutions containing 25 nM AP6 with 4 hemes bound and varying 
cytochrome c concentrations were mixed with equal volumes of a solution containing 
20 µM decylubiquinone.  Data was fit to steady state kinetics of an enzyme with a 
single substrate to determine initial velocities and kinetic parameters. 
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several other quinone molecules are able to successfully initiate AP6 turnover (Figure 
4.5).  We have determined that, like cytochrome b6f found in chloroplasts and 
cyanobacteria [19], decylplastoquinone yields AP6 turnover that is slightly faster than the 
turnover reported for decylubiquinone.  In addition to varying the R-groups on the 
quinone ring, the isoprene tail of the molecule can also be varied to some degree with 
successful enhancement of the background rate.  Ubiquinone-2 does reduce AP6, though 
at a slower rate than the decylquinone molecules. However, it was more difficult to add 
the extremely water-insoluble ubiquinone-50, which is the natural substrate for Complex 
III in chromatophore membranes. Adding the UQ-50 with DPC detergent side steps some 
of these solubility issues and leads to enhanced activity in the presence of AP6.  
 
 
Figure 4.5: Varying the quinone substrate: decylubiquinone (green), 
decylplastiquinone is added (orange), and  ubiquinone-2 (blue).  Ubiquinone-50 in 
organic solvents was inactive (red), but did show activity when solubilized in a solvent  
and 2 mM DPC mixture (purple).   
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 4.3.3 Observing changes in AP6 activity in the presence of oxygen. The 
experiments described above were performed anaerobically to minimize the role played 
by oxygen.  However, when AP6 activity assays were performed in the presence of 
oxygen, the addition of SOD does not change the amount of cytochrome c reduced 
(Figure 4.6); this indicates that reduction of cytochrome c by quinol via AP6 in the 
presence of oxygen is not dominated by a superoxide-mediated mechanism.  
 
Figure 4.6: The assay was completed under aerobic conditions to see if oxygen was 
required for AP6 activity.  Though the presence of oxygen does increase the number 
of turnovers AP6 can complete (green), it does not change the turnover rate observed 
in anaerobic conditions (red).  However, adding superoxide dismutase prior (blue) or 
after (purple) the addition of AP6 does not limit AP6 activity, suggesting superoxide 
is not formed in this reaction in high enough quantities to have an effect on the 
reaction rate. 
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4.4 Discussion 
 As shown in Figure 4.2 and Table 4.1, AP6 clearly demonstrates significant 
quinol-cytochrome c oxidoreductase turnover, being the first maquette protein to match 
near-natural levels of activity.  Here we outline a model for how AP6 functions so well 
and suggest a role for our designs in understanding more complicated electron transfer 
systems in the mitochondria. 
 4.4.1 Developing a model for AP6 heme reactivity.  There are several 
possible combinations for heme binding in AP6 when four hemes are bound, and it is 
certainly possible that our assays actually contain a mixture of AP6 proteins that have 
different arrangements of heme binding.  However, based on the heme affinity studies 
completed in chapter four, we assume that the AP6 that is most populated in this assay 
has two hemes bound in the heme binding site located in the water soluble extension of 
the 4-helix bundle (histidine 10) and two hemes bound in the nearest membrane binding 
site (histidine 24).  Even without a heme in the third membrane binding site (histidine 
35), the electron transfer distance between the second heme and cytochrome c would be 
Table 4.1 Summary of AP6 activity 
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4
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approximately 8.5 Å, which is still allows for electron transfer reactions to occur on the 
millisecond timescale we observe in these experiments. 
 Figure 4.3 illustrates that AP6 activity is halved when only one heme is bound.  
Due to cooperative heme binding in AP6, when one heme equivalent is added, there are 
two distinct populations of AP6 present – 50% apo-protein, and 50% of AP6 with two 
hemes bound.  Therefore, as the concentration of active AP6 is cut in half, it is not 
surprising that AP6 can only reduce cytochrome c at half the rate.  Additionally, apo-
proteins present will interact with cytochrome c substrate molecules, impacting the 
amount of substrate available to active AP6. 
 It is known that oxygen can interact with reduced quinones to produce superoxide 
intermediates that can in turn reduce cytochrome c.   Indeed, the presence of oxygen 
leads to substantial background rates when quinone and cytochrome c (but not AP6) are 
present.  In order to eliminate oxygen from contributing to the background rate and/or the 
measured enzymatic rate, the assays were conducted under anaerobic conditons.  
Additionally, AP6 was exclusively solubilized in DPC, a detergent micelle system that 
does not allow for the formation of an AP6 oxy-ferrous intermediate state.  However, as 
the natural Complex III can generate superoxide upon turnover (under certain redox 
conditions), it was necessary to test whether or not AP6 quinol-cytochrome c turnover 
also generated superoxide in the presence of oxygen, and if limiting superoxide 
production in the aerobic assay caused a dramatic difference in AP6 turnover rate. 
 The turnover rate of AP6 was unaffected in the presence of oxygen, though the 
total amount of cytochrome c reduced was increased (Figure 4.6).  However, the addition 
of SOD to the reaction cuvette did not limit AP6 activity or quench turnover.  This 
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suggests either that the levels of superoxide generated in this assay are not high enough to 
activate SOD, or that the role of oxygen in this reaction is limited.  It is also possible that 
any superoxide formed in the presence of oxygen is rapidly converted to hydrogen 
peroxide (and thus, not quenched in the presence of SOD); however, levels of hydrogen 
peroxide cannot be tested under these assay conditons because cytochrome c is an 
indirect redox partner for the horseradish peroxidase system commonly used to measure 
hydrogen peroxide concentrations.   
 4.4.2 Thermodynamic constraints on AP6 activity.  The initial transition from 
quinol to semiquinone as an electron is transferred to AP6 is an uphill step, and is 
thermodynamically unfavorable (Figure 4.7).  However, a similar uphill step is expected 
in native Complex III as a reduced quinol molecule at the Qo site transfers an electron to 
oxidized FeS [20, 21].  We expect the uphill step in AP6 to be much larger than in native 
Complex III, which may explain why the reaction is slower (Figure 4.7).  Changing the 
thermodynamics of this very important electron transfer step may prove to enhance AP6 
turnover.  Work ongoing in the laboratory involves modifying AP6 to bind hemes with 
significantly higher midpoint potentials, such as heme a.  In the meantime, altering the 
thermodynamics of this reaction was explored with HP7, which has already been 
engineered to accommodate a variety of heme cofactors, as detailed in chapter five. 
 4.4.3 AP6 activity is not decylubiquinone specific.  It is not surprising that 
AP6 is able to receive electrons from a variety of quinone substrates, as a specific 
quinone binding pocket within the protein was not engineered.  Also, though most 
Complex III proteins use pools of ubiquinone as substrates for the Qo and the Qi site, 
their activity is not dependent on ubiquinone specifically – Complex III activity is  
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Figure 4.7:  The thermodynamics of Complex III and AP6 electron transfer are 
structured in a similar way. Both Complex III (top) and AP6 (bottom) have 
reactions that are unfavorably uphill followed by favorable (downhill) reactions.  
In Complex III, the uphill step is the initial electron transfer reaction between the 
QH2/SQ at the Qo site and the FeS cluster, and in AP6, the QH2/SQ to heme b 
electron transfer step is unfavorable.  Quinol reduction of AP6 is four times more 
unfavorable than the uphill step in Complex III, and could account for the 
difference in AP6 and Complex III activity. 
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maintained when alternative quinones are substituted into the Qo site [22].  Particularly 
since plastoquinone is used naturally by cytochrome b6 f, a Complex III analog, it was 
expected that plastoquinone and ubiquinone would work equally well as electron donors 
in this assay. 
 Depending on the substituents or the length of the isoprene tail, different quinones 
will interact with AP6 differently.  Based on the quinones tried in this work, the isoprene 
tail seems to dictate AP6 activity levels, presumably due to their regulation of quinol-
AP6 proximity.  Hydrophobic quinones such as decylplastoquinone and decylubiquinone 
will associate with the detergent micelle better because they have more isoprene groups, 
bringing the quinol closer to the b hemes bound to AP6.  Not surprisingly, AP6 turnover 
is the essentially the same in the presence of either of these substrates.  Though 
ubiquinone-2 is also capable of acting as an electron donor to AP6, it likely does not 
associate with the detergent as well due to a much shorter hydrophobic tail, limiting its 
electron transfer with AP6. 
 4.4.4 Estimating semiquinone stability of the “Q-pool” and Q-heme b 
electron transfer distances.  The rate of electron transfer through AP6 is likely to be 
dependent on the individual one-electron redox couples of the two-electron quinone 
substrate—that is, on the stability constant of the quinone substrate.  When the midpoint 
potential of the first electron added to fully oxidized quinone is more negative than the 
midpoint potential of the second electron, then the intermediate semiquinone is unstable 
and the stability constant is less than 1.  Electron tunneling rate calculations give us some 
idea of what the tunneling distance and stability constants might be.  Here we work with 
quinones that all have very similar semiquinone stability, but we can model the effect 
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varying semiquinone stability would have when the midpoint potentials of the hemes in 
AP6 are fixed using the Moser-Dutton equation (Figure 4.8).  In order to achieve the 
 
Figure 4.8:  The Moser-Dutton equation for calculating electron transfer rates was 
used to model ranges of semiquinone stability and electron transfer distances that 
would produce AP6 turnover on a given timescale.  Shown on the y-axis are values for 
the semiquinone stability constant on a logarithmic scale, and depicted on the x-axis 
are values for the electron transfer distance between the AP6 hemes and cytochrome c.  
Each line depicts a timescale (logarithmic scale), with the lines in bold indicating 
nanoseconds (-9 in box), microseconds (-6), milliseconds (-3), and seconds (0) and 
dashed lines indicating ranges in between these values.  As the kcat of AP6 indicates 
each turnover occurs on a millisecond timescale, we were particularly interested in the 
values falling within the light green range of the graph. 
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reaction on a millisecond timescale, the semiquinone stability constant of the Q-pool 
would need to be between 10-9 to 10-20, indicative of an unstable semiquinone 
intermediate.  Therefore, it is most likely that the quinone here does not form an 
appreciable semiquinone intermediate at all, but transfers two electrons concertedly to 
two of the hemes bound to AP6.  This also agrees with our observation that only two 
hemes are required to achieve maximal activity (Figure 4.3). 
 As no structural data exists for the substrate-AP6 complexes in this assay, the 
exact electron transfer distances between the cofactors are unknown and could also affect 
enzyme turnover.  We can use the heme binding information known about AP6 along 
with docking studies of cytochrome c and Complex III [23] to assume the electron 
transfer distance between the b-hemes bound to AP6 and the c-heme in cytochrome c to 
be approximately 8.5 Å.  This assumption allows us to model possible distances between 
the reduced quinol molecules and the AP6 hemes, which is more of an unknown because 
there is not a fixed binding site for quinol within AP6.  As indicated by Figure 4.8, to 
achieve a reaction on a millisecond timescale (green section of graph), the distance 
between the quinol and heme b is limited to a range of 3.5 – 7.5 Å if the semiquinone is 
unstable.  Short electron transfer distances between the heme and quinol could reasonably 
occur; the hydrophobicity of the quinone molecule allows it to partially associate with the 
DPC detergent micelle, shortening the distance the electron has to travel between the 
quinone and AP6’s heme cofactors.  Additionally, it is possible that the quinone pool in 
this experiment is associating with AP6 non-specifically, as this behavior has been 
observed for other synthetic proteins [24].  This would enable the quinone to partition 
into the hydrophobic core of the protein, promoting a stronger interaction with hemes 
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bound to AP6 at very short distances.  Quinone/heme electron transfer appears quite 
possible using the simple enzymatic principle of proximity--securing quinone at a 
specific binding site or manipulating the quinone stability constant through specific 
interactions with the protein do not appear essential for catalysis. This simple proximity 
model for quinone reactivity with heme proteins is not an unrealistic representation of 
how these electron transfer processes occur in biological membranes; it is well-
established that the ubiquinone at the Qo site is highly mobile, initiating Complex III 
turnover when it is bound.  As no evidence for specific quinone-protein interactions have 
been established at Qo, it is reasonable to assume that our experiments demonstrate a 
very important piece of biological engineering – quinone concentrations need only to be 
in excess at a particular active site in order to generate substantial turnover.   
 This model could be tested through the development of an AP6 protein that 
contains a quinone amino acid fixed in position within the soluble region of the maquette.  
Previous experiments incorporating a napthoquinone amino acid, Naq, into a small 
peptide have demonstrated that Naq is spacially equivalent to a tryptophan residue [25].  
Therefore, Naq can be readily added to the AP6 peptide sequence without large 
disruptions in protein assembly or heme binding.  Fixing the quinone into one position in 
the maquette would answer definitively whether or not quinone-protein interactions are 
essential for maximal enzymatic turnover.   
4.5 Conclusion 
 This work was able to translate a complicated mitochondrial redox enzyme into a 
simple, transmembrane electron transfer chain that still retained all of the necessary 
engineering elements to accomplish quinol-cytochrome c oxidoreductase activity within 
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two orders of magnitude of the natural rate.  The hemes bound to AP6 were able to 
receive electrons from quinone substrates and reduce cytochrome c on a millisecond 
timescale.  Figure 4.9 compares AP6 activity to the turnover rates for previous de novo 
designed enzymes [5-7], the background rate for quinol to cytochrome c electron transfer, 
and Complex III steady-state turnover rates.  AP6 improves upon the catalytic rates of 
other designed oxidoreductases, and begins to bridge the gap between the rate of 
uncatalyzed cytochrome c reduction and the rate of Complex III turnover.     
 
Figure 4.9 Comparing AP6 (green arrow) kcat to other de novo designed enzymes (red 
arrows) [5-7], and natural turnover rates (black arrows). 
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Chapter 5:  Testing the thermodynamic limits of 
maquette quinol-cytochrome c oxidoreductase 
activity  
 
 
 
As shown in chapter four, the electron transfer between a quinol molecule and the AP6 
maquette is a drastic uphill reaction, and limits the rate at which AP6 can turnover.  
However, if the midpoint potential in the maquette were raised, the thermodynamic 
barrier for quinol to heme electron transfer would be lowered.  In this chapter, the effect 
of modulating maquette midpoint potential on the rate of cytochrome c reduction is 
determined.  For these studies, a library of soluble maquettes was chosen, primarily 
because they are able to bind a variety of heme-based cofactors in addition to heme b, 
yielding a wider range of midpoint potentials to test. From measuring the activity of 
proteins that have a range of different midpoint potentials, the thermodynamic limit for 
quinol-cytochrome c activity by a soluble maquette was determined for this assay.  HP7 
maquettes that contain hemes with measured midpoint potentials lower than -150 mV are 
inactive, indicating that the quinol/semiquinone to heme electron transfer step has 
reached an insurmountable thermodynamic barrier.   
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5.1 Introduction 
 Chapter four revealed AP6 to be the first synthetic enzyme to achieve near-natural 
levels of Complex III enzymatic activity.  However, one potential limitation on its 
turnover rate is the uphill electron transfer step between quinol and AP6.   In order for 
this electron transfer reaction to become more favorable, the midpoint potential of hemes 
bound to AP6 needs to be raised.  One convenient way to lower the thermodynamic 
barrier for quinol to maquette-cofactor electron transfer is to substitute the FePPIX 
cofactor bound with hemes that have higher midpoint potentials.  However, though AP6 
	  
 
Figure 5.1: Structures of heme-based cofactors available to bind to HP7.  Heme b (in 
the form of protoporphyrin IX) is shown in red, heme a and diacetyldeuterioporphyrin 
IX (a heme a mimic) in green, and iron(III)-dicyanodeuteroporphryin in teal. 	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can successfully bind Fe- and ZnPPIX [1], its binding sites have not demonstrated tight 
binding with other porphyrin-based cofactors.  
 Soluble maquettes have been modified to bind a variety of different heme 
cofactors [2-8].  HP7 was chosen for this study because it is extremely well characterized 
[6] and shares sequence identity with the HP domain found in AP6.  Shown in Figure 5.1 
are the structures of four cofactors that can bind tightly to HP7 – heme b, heme a, 
iron(III)-dicyanodeuteroporphyrin (dicyano), and iron-2,4-diacetyldeuterioporphyrin IX 
	  	  
Figure 5.2: Absorbance spectra for HP7 with 1 cofactor equivalent bound.  Shown in 
green is HP7 with heme a bound, in red HP7 with heme b, in blue HP7 with iron-2,4-
diacetyldeuterioporphyrin IX (data courtesy of Ross Anderson) and in teal HP7 with 
iron(III)-dicyanodeuteroporphryin. 	  
	   107	  
(DADPPIX) – and Figure 5.2 depicts characteristic absorbance spectra for each of the 
HP7-heme complexes. In heme a, the FePPIX C-8 methyl group is oxidized into a formyl 
group, and the vinyl group on C-2 is converted into a hydroxyethylfarnesyl side chain.  
DADPPIX is a heme a analog that substitutes the two vinyl groups found in FePPIX for 
acetyl groups. The dicyano heme is very similar in structure to DADPPIX, with the acetyl 
groups replaced by nitrile groups.  A c-type HP7 protein also exists; however, heme c 
was not chosen for this work because its absorbance profile overlaps with that of the 
natural cytochrome c monitored in the assay (Figure 5.2).   
 Electron withdrawing groups present in heme a and DADPPIX have been shown 
to be responsible for raising the midpoint potential  of maquettes upon binding, in 
comparison to when heme b is bound.  For example, the presence of the electron 
withdrawing formyl group in heme a has been shown to raise the midpoint potential of 
soluble maquettes by destabilization of the ferric state [2, 4].  The midpoint potential of 
FePPIX in HP7 [6] (Table 5.1) is considerably lower than has been observed for its 
soluble maquette predecessors [4, 9], and it was expected that the midpoint potential of 
HP7 would be substantially increased by the introduction of electron withdrawing 
substituents on the heme because HP7 has a net charge of -14.  The range of midpoint 
potentials available within the HP7 design allows for the direct control of quinol to heme 
electron transfer thermodynamics, yielding an opportunity to directly test whether 
manipulating maquette midpoint potential is enough to dictate its enzymatic function.   
5.2 Materials and methods 
 5.2.1 Maquette preparation.  All soluble maquette proteins were designed and 
synthesized by other members of the laboratory, and concentrated stocks of each protein 
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were donated for the completion of this work.  Stocks of HP7 were obtained from Ross 
Anderson and BT3 was obtained from Tammer Farid and Bruce Lichtenstein.  All 
concentrated stocks were diluted to their final concentrations with a 250 mM pH 9 borate 
buffer containing 100 mM potassium chloride, as both of the soluble maquettes required 
alkaline pH conditions to bind heme cofactors.    
 5.2.2.  Heme stock preparation. A 1 mM stock solution of hemin (Sigma) was 
prepared in 20 mM potassium hydroxide and its concentration was verified using a 
standard hemochrome difference spectrum, as described by Berry et al [10].    Stocks of 
dicyano in DMSO were obtained from syntheses completed by Bruce Lichtenstein [11].  
Stocks of heme a in DMSO were obtained from Ross Anderson. 
 5.2.3 Heme binding.  Each of the soluble maquettes has the capacity to bind up 
to two heme cofactors.  Based on the concentration of the protein stock, the concentration 
of the heme stock needed to add 0.1 aliquot was determined.  Hemes were titrated into 
the maquettes in 0.1 aliquots until the desired number of equivalents was added into the 
solution.  Then, the maquettes were passed down a PD-10 desalting column to separate 
unbound heme from the maquette-heme complex.  This procedure was modified from a 
protocol published previously [6].  Samples of HP7 with DADPPIX bound were obtained 
from a frozen stock made by Ross Anderson, and did not require this step. 
 5.2.4 Midpoint potential determination. Equilibrium redox potentiometry was 
used as a functional analysis of the oxidation and reduction of hemes bound to HP7.  
Redox titrations were performed in a similar fashion to those completed in previous 
chapters using an anaerobic 1 mL cuvette (Starna Cells) equipped with a combination 
electrode (Microelectrodes Inc.). All of the potentials reported are in reference to the 
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normal hydrogen electrode (NHE).  The reduction potential of the cuvette solution was 
adjusted by adding microliter aliquots of freshly prepared solutions of either sodium 
dithionite (for reducing) or potassium ferricyanide (for oxidizing). 20 µL of a stock 
solution containing the following redox mediator dyes was also added to the solution 
(final concentrations reported): 5 μM 1,2-naphthoquinone, 5 μM 1,4- naphthoquinone, 20 
μM duroquinone, 10 μM pyocyanine, 5 μM indigotrisulfonate, 10 μM 2-hydroxy-1,4-
naphthoquinone, 1 μM indigocarmine, 10 μM anthraquinone-2-sulfonate, and 5 μM 
benzyl viologen. After equilibration at each midpoint potential, the UV-visible spectrum 
of the maquette was recorded, monitoring in particular the increase in the sharp a-band 
absorption for each heme relative to a reference wavelength.  The data were analyzed 
using the Nernst equation, fitting to an n=1 electron transfer process. 
 5.2.5 Enzyme steady state activity measurements. As described in chapter 
five, maquette functionality as a quinol-cytochrome c oxidoreductase was measured via 
its reduction of cytochrome c in the presence of excess decylubiquinol [12]. A solution of 
25 µM horse heart cytochrome c (Sigma) in redox buffer (50 mM potassium phosphate 
and 100 mM potassium chloride at pH 8) and 10 µM decylubiquinone was incubated 
anaerobically in a 3 mL cuvette and stirred for one minute, after which a maquette protein 
was introduced into the cuvette in nanomolar concentrations (100 nM). Using an 
extinction coefficient of 18.5 mM-1cm-1 for the 551 nm – 540 nm difference absorption, 
cytochrome c reduction was monitored over time until the amount of cytochrome c 
reduced reached a constant maximum. 	   For HP7 maquette complexes that demonstrated activity, this cuvette assay 
was modified for anaerobic stopped flow experiments.  An Olis multiwavelength stopped 
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flow spectrometer was used to measure cytochrome c reduction over 200 s.  100 mL from 
a syringe containing 20 mM decylubiquinone in reaction buffer and DMSO was mixed 
with 100 mL from a syringe containing 200 nM HP7 and 50 µM cytochrome c.   
 
Table 5.1 Midpoint potentials and kcat  values at pH 8 
Protein Em8 (mV) Em8 reference kcat (s-1) 
HP7 FePPIX -280 Ron Koder [6] 0.0062 
HP7 heme a -72 This work 0.54 
HP7 
dicyanoheme 
+62 This work 0.63 
HP7 DADPPIX -147 Ross Anderson [13] 0.21 
dicyano heme n.d. n.d. 1.2 
AP6 -150, -75 This work 4.1 
 
5.3 Results 
 5.3.1 Determining the 
midpoint potentials of 
alternative hemes bound to 
HP7. The midpoint potentials 
of hemes bound HP7 are 
reported in Table 5.1.  The 
acetyl groups found in 
DADPPIX were found to raise 
the midpoint potential of HP7 
by 133 mV through weakening 
	  
 
Figure 5.3: Redox titration of 5 µM HP7 with 1 
equivalent of heme a.  Data was fit using the Nernst 
equation with Igor Pro (Wavemetrics Inc.) software. 	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the affinity of the bis-histidine 
site for the heme iron [13], as 
has been observed for other 
soluble maquettes [14].  As 
shown by the redox titrations in 
Figures 5.3 and 5.4, heme a 
and dicyano also raised HP7 
midpoint potential 
substantially.  The midpoint 
potential of bound heme a at 
pH 8 is -72 mV, or 200 mV more positive than the potential measured for heme b.  The 
midpoint potential of the dicyano heme in HP7 was 62 mV at pH 8, an astounding 342 
mV higher than heme b in HP7.  This translates to a lower free energy for quinol to heme 
electron transfer up to 33 kJ when heme b is substituted with alternative heme cofactors 
in HP7.   
 5.3.2 Comparing AP6 activity to soluble maquette proteins. HP7 quinol-
cytochrome c oxidoreductase activity was determined using the steady-state turnover 
assay discussed in chapter four (Figure 5.5) [12].  Shown in purple is the background rate 
of cytochrome c reduction by DBH.  The addition of the HP7-heme b maquette did not 
enhance this rate  (yellow trace), but HP7 demonstrated increasing levels of catalysis as 
its midpoint potential was raised.  HP7-DADPPIX activity (red) was an order of 
magnitude faster than the background rate and HP7-heme a (green) was twenty times 
faster.  A heme b control trace is shown in Figure 4.2; neither DADPPIX nor heme a in  
	  	  
Figure 5.4: Redox titration of 5 µM HP7 with 1 
equivalent of iron(III)-dicyanodeuteroporphryin.  
Data was fit using the Nernst equation with Igor Pro 
(Wavemetrics Inc.) software.  	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Figure 5.5 Quinol-cytochrome c oxidoreductase activity is shown for several 
different maquette proteins.  Activity was quantified as the absorbance difference 
between reduced (550 nm) and oxidized (540 nm) cytochrome c over time.  All 
experiments were completed using buffered solutions containing 100 mM 
potassium chloride and 50 mM potassium phosphate (pH 8.0).  25 µM cytochrome 
c was incubated in a cuvette to establish a baseline absorbance, and then a 
concentrated solution of DBH was added to establish a final concentration of 10 
µM in the cuvette.  After the background rate of direct quinol to cytochrome c 
electron transfer was established (purple), the maquette proteins were added to the 
cuvette. The soluble maquettes were added at a final concentration of 100 nM.  
HP7 (yellow) with heme b did not have activity that was significant when 
compared to the background rate.  However, when cofactors such as DADPIV 
(red) and heme a (green) were incorporated into HP7, HP7 activity increaed 
significantly. Experiments with 25 nM AP6 (blue) were conducted slightly 
differently than those with the soluble maquettes, as AP6 required the assay buffer 
to also contain 2 mM DPC.  AP6 activity was greater than even the most 
catalytically-active form of HP7, 100 nM HP7 with heme a bound.  	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Figure 5.6 Quinol-cytochrome c oxidoreductase activity is shown for HP7 and 
AP6 with iron(III)-dicyanodeuteroporphryin (dicyanoheme) bound.  Activity 
was quantified as the absorbance difference between reduced (550 nm) and 
oxidized (540 nm) cytochrome c over time.  All experiments were completed 
using buffered solutions containing 100 mM potassium chloride and 50 mM 
potassium phosphate (pH 8.0).  25 µM cytochrome c was incubated in a cuvette 
to establish a baseline absorbance, and then a concentrated solution of DBH was 
added to establish a final concentration of 10 µM in the cuvette.  After the 
background rate of direct quinol to cytochrome c electron transfer was 
established (purple), the maquette proteins were added to the cuvette. Though 
100 nM HP7 (green) had considerable activity with 1 equivalent of the 
dicyanoheme bound, adding 100 nM dicyanoheme (red) as a control 
demonstrated more activity than when it is bound to the maquette. 	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the absence of HP7 generated activity above the DBH background rate (data not shown). 
Complementary stopped-flow experiments were completed to resolve the kcat values for 
the various proteins tested in this assay (Table 5.1).  When alternative hemes were bound, 
HP7 had kcat values that were approximately an order of magnitude slower than AP6. 
 As shown in Figure 5.6, the HP7-dicyano maquette was more reactive than any of 
the other HP7 complexes; however, the dicyano heme control experiment revealed that 
the activity of the dicyano heme is greater in solution than bound to the protein, and is 
almost equivalent to the quinol-cytochrome c oxidoreductase activity shown for AP6.  
This was a surprising result, as none of the other hemes reacted as well in solution as they 
did when incorporated into a maquette.   
5.4 Discussion 
 5.4.1 Approaching and exceeding the thermodynamic limit for quinol to 
heme electron transfer.  HP7 is able to maintain turnover over a remarkably wide 
range of for quinol to heme energy differences.  As the barrier for quinol to heme 
electron transfer is raised successively, HP7 activity decreases.  However, the 
quinol/semiquinone to heme electron transfer step reaches an insurmountable 
thermodynamic barrier when heme b is bound to HP7 and HP7 midpoint potential drops 
to -280 mV.  Under these conditions, HP7 no longer contributes to cytochrome c 
reduction, and only the DBH background reduction of cytochrome c is observed. 
   Midpoint potential differences between the different cofactors bound to HP7 can 
explain most of the results in this chapter.  One unexpected finding was free dicyano 
heme displaying higher catalytic behavior in solution relative to when it was bound to 
HP7.  This can be explained in part due to the impact dicyano heme binding has on HP7 
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mobility.  Bruce Lichtenstein demonstrated that the HP7 histidines are tightly bound to 
the reduced dicyano heme, eliminating HP7 helical rotations and oxyferrous generation 
[11].  This indicates that this heme is buried within the core of the HP7 four-helix bundle 
when it is bound, and much less accessible to diffusible substrates than it is in solution.    
 5.4.2 Impact of thermodynamic threshold on future AP6 designs.  Though 
this study revealed that lowering the thermodynamic barrier for quinol to heme electron 
transfer significantly improved HP7 turnover rate, it also validated the design of 
transmembrane maquette proteins.  AP6 was still a better enzyme than HP7 even when its 
reduction reaction was more unfavorable, suggesting that the midpoint potential of the 
heme is not the most important factor for reproducing Complex III activity in a synthetic 
enzyme.  Instead, AP6’s strong interactions with its quinol and cytochrome c redox 
partners is likely what makes it turnover at a near-natural rate.  The hydrophobic 
environment provided by AP6 and/or its membrane interface helps the quinone substrate 
bind closer to the AP6 hemes than it can in solution.  Additionally, AP6 has the same 
binding affinity for cytochrome c that natural Complex III does for cytochrome c2, which 
is not reproduced in HP7.   
 Still, lowering the thermodynamic barrier for AP6 turnover could increase its 
enzymatic activity, as was demonstrated for HP7.  Subtle residue mutations around the 
heme binding sites could change the electrostatic environment of the heme and may be 
enough to shift AP6 midpoint potential.  Shifman et al. determined that the elimination of 
glutamate residues around the heme binding site of H10A24 raised the midpoint potential 
of the hemes bound by 50 mV [4].  There are two glutamate residues, residues 11 and 12, 
near the “a” binding site in AP6 that could be mutated to a neutral (but polar) residue like 
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glutamine to raise AP6 midpoint potential.  However, charge modifications have a higher 
propensity for unexpected results and could require several iterative designs to see any 
changes to the redox environment.  Shifman et al. also observed that some mutations had 
no effect because the rotation of the assembled helices was altered depending on the 
charges on the helix, driving mutated residues away from the hydrophobic core and 
reducing their effect [4]. 
 In the meantime, AP6 could be redesigned to be more accommodating to 
alternative heme cofactors that would raise its midpoint potential. AP6 may be limited in 
the cofactors it can bind tightly because it currently does not have any designed-in control 
over its structural assembly. Structural constraints could be implemented into the AP6 
design to limit conformational flexibility and promote alternative heme binding.  A loop 
sequence (GGSGCGSG) would link two sets of two AP6 helices through a disulfide 
bond, yielding the single “candelabra” structure adopted by HP7.  This new design would 
require the development of an AP6 expression system, as the length of two AP6 helices 
linked by the loop sequence would far exceed what is recommended for solid-phase 
peptide synthesis. 
5.5 Conclusion  
 This work clearly demonstrated that quinol to heme electron transfer is the rate-
limiting step for maquette turnover.  Raising the midpoint potential of the HP7 model 
system, and therefore lowering the thermodynamic barrier for quinol to heme electron 
transfer, increased both HP7 catalytic rate and the total amount of cytochrome c substrate 
reduced.   	   This work also revealed that transmembrane maquettes are able to perform 
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electron transfer functions that are inaccessible to soluble protein designs.  When HP7 
activity was maximized, it still reduced cytochrome c an order of magnitude slower than 
the AP6 design. This suggests that having a favorably redox-active maquette is not the 
minimum requirement for generating successful model systems to study mitochondrial 
respiratory chain electron transfer processes. The main functional elements involved in 
biological energy transduction are invariably contained within membranes and directed 
vectorially across these membranes.	  Therefore, creating a library of maquettes capable of 
reproducing key steps in energy transduction depends upon the redesign and expansion of 
the AP maquette family. 
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Chapter 6:  Conclusions  
 
 
 
 
 
 
 
 
 
 
 
Complexity is not an essential requirement for transmembrane proton and electron 
transfer.  The work in this thesis has generated a list of important engineering elements 
that dictate Complex III activity and supports a simple model for Complex III turnover 
where electron tunneling reactions are rate-limiting.  In this chapter, I will discuss the 
implications this kind of model will have on the field of Bioenergetics and suggest future 
directions that could be explored to define a mechanism for Qo oxidation.  Portions of 
this chapter have been included in the following references and are reprinted with 
permission from SpringerLink and the Journal of Bioenergetics and Biomembranes [1, 
2]. 
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6.1 Complex III assembly instructions  
 While there is still progress to be made in the field of de novo design, artificial 
proteins display redox functional characteristics that are within reach of the engineering 
of natural enzymes [3-5].  The main goal of the maquette approach is to uncover the 
assembly instructions required to put together biological functions by asking basic 
questions about how proteins work:  How many engineering elements are required?  
What are the structural and biochemical tolerances of those elements?  What portions of 
structure dictate function and what portions can be ignored?  This thesis work aimed to 
disassemble the complicated history of Complex III and start from scratch, building 
quinol-cytochrome c function one engineering element at a time.  
 To design AP6 to have quinol-cytochrome c oxidoreductase activity, the main 
elements of these electron transfer reactions in Complex III were extracted and 
incorporated into AP6: simple α-helical structure to provide a secure, linear scaffold for 
securing cofactors, both hydrophilic and hydrophobic sections of amino acids to promote 
interactions with both the membrane and soluble molecules, multiple histidine sites for 
heme ligation, and a tryptophan molecule for convenience when determining AP6 
concentration.   
6.2 Developing a simpler model for Complex III electron transfer 
   Natural electron transfer chains convert the steep exponential fall-off of electron 
tunneling rate with distance to a near linear dependence [7].  Chains of cofactors become 
more tolerable to uphill reactions as the chain becomes extended [8].  One of the reasons 
heme c1, along with other cofactors in Complex III, is able to accommodate large changes 
to its active site residues and redox potential is that Complex III is made up of a large 
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chain of cofactors that can compensate for slight changes in the thermodynamics of a 
single electron transfer event.  Many complicated mechanistic proposals exist that predict 
specific structural elements of Complex III active sites that dictate their redox behavior 
[1, 9, 10].  Yet when these residues are eliminated, as they were for heme c1 in chapter 
two, the equilibrium midpoint potentials of the cofactor are unaffected and enzyme 
turnover remains unscathed.  Perhaps future experiments and models should begin to 
question not what singular engineering elements Complex III relies on for catalytic 
efficiency, but instead what groups of things work together collectively to minimize the 
costly short-circuits that can be caused by a single electron transfer step.  
 With no obvious quinone-binding site included in our protein design, AP6 
provides clear evidence that a specific quinone-binding site within a membrane protein is 
not essential for generating significant quinol-cytochrome c oxidoreductase enzymatic 
activity from a heme protein.  Proximity of reduced quinol substrates to the hemes in AP6 
is accomplished simply by adding an excess of quinone substrate that is free to partition 
through the hydrophobic membrane interface.  This same reserve of excess quinone 
exists in the mitochondrial respiratory chain as the Q-pool.  The absence of Qo from 
Complex III crystal structures [11-13] suggests that it is mobile [14], diffusing freely 
between the Q-pool and its active site.  In fact, Qo mobility may help Complex III 
regulate unwanted short-circuit reactions.  If Qo is only in its active site during forward 
turnover, this would be one way of promoting energy transduction over unwanted reverse 
electron transfer reactions.   
 Though the contradictions between various experimental results leaves the 
mechanism of the Qo site undefined, that does not necessarily mean that the mechanistic 
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suggestions for Complex III turnover need to be overly complex.  Qo bifurcation is well 
understood, but the reversible and robust nature of Complex III electron transfer dictates 
that the high and low potential chains are inextricably linked.  Instead of dividing 
Complex III into two separate pathways (Figure 1.3), Complex III can instead be thought 
of as a single chain (shown in Figure 6.1) [6, 8], where shifting the equilibrium of one 
reaction (i.e. midpoint potential or cofactor distance changes) affects the equilibrium of 
all of the remaining reactions in the cofactor chain.  Figure 6.1 is drawn to depict 
Complex III as a functional monomer, but this simplistic view would still hold true for a 
functional Complex III dimer; the two single chain monomers would just be 
electronically connected through their bL sites.  The distribution of electron equivalents 
within Complex III is solely dependent on the rates of each of the reversible partial 
reactions, which include all electron tunneling steps, Qo exchange to and from its active 
sites, and the distal and proximal movement of FeS. 
Recently, Cieluch et al. proposed a similar model based on the results of their 
experimental work that modified residues around the R.capsulatus heme c1 binding site to 
manipulate heme c1 midpoint potential [6].  In flash experiments without inhibitors 
added, they observe that the completion of two Qo turnovers and reduction of Qi leaves 
the FeS cluster and c1 saturated with electrons.  This reaction is driven to completion 
even in Complex III mutants where the midpoint potential of heme c1 is 100 mV lower 
than that of the FeS cluster and the electron transfer reaction is uphill.   
When the outflow of electrons from the b-chain is blocked by the addition of 
antimycin in wild-type Complex III, both b-hemes remain reduced for a significant 
amount of time because the low potential chain becomes saturated with electrons.  This  
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Figure 6.1: A single chain view of Complex III.  A similar model was 
proposed by Cieluch et al [6].  In this model, Qo is still delivered to its binding 
site from a membrane-bound Qpool, but Qo bifurcated oxidation is depicted as 
two half-reactions along the same chain rather than considering the high and 
low potential chains of Complex III to be two separate electronic paths.  Under 
these conditions, the equilibrium reactions for each redox step can directly 
affect any of the other equilibrium reactions occurring in Complex III. 	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effectively shifts the equilibrium at Qo, as the probability for reverse reactions with 
reduced bL is greater with the increase in the effective concentration of reduced heme bL.  
Likewise, the equilibrium at Qo can also shift as the concentration of reduced FeS cluster 
increases, as this substrate can also initiate short-circuit reactions with Qo.  The mutants 
described by Cieluch et al. shift the Qo equilibrium in this way by manipulating the FeS-
c1 barrier.  The electron distribution in the b-chain of these mutants is directly impacted 
by fluctuations in the electron distribution within the c-chain.  Therefore, because Qo 
reactions can occur reversibly, their work confirms that the bifurcation reaction in 
Complex III does not imply that Complex III transfers electrons to two totally 
independent redox chains, but that the electrons simply travel in opposite directions from 
Qo within the same single chain of cofactors. 
6.3 Impact of this work on future experiments 
6.3.1 Exploiting Complex III thermodynamics to access Qo states.  While 
spectroscopically accessing short-circuit states (Figure 1.6) may stay out of experimental 
reach for some time to come, stabilizing the green enzyme-substrate and enzyme-product 
intermediates will be the key to defining the Qo site mechanism.  Chapter five revealed 
that manipulating the thermodynamics of a rate-limiting electron transfer step would 
modify the reactivity of an enzyme.  This concept could conceivably be applied to the Qo 
oxidation reaction in order to stabilize two key intermediates – Qo fully reduced and Qo 
fully oxidized (green states in Figure 1.6). The following thermodynamic manipulations 
could be applied to control Qo site reactivity:  1) replacing ubiquinone with other 
quinones and analogues that have either a higher redox midpoint potential, such as 
plastoquinone (PQ) and benzoquinones (BQ), or a lower redox potential, such as 
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menaquinone (MQ); and 2) using mutants to lower the midpoint potential of FeS or raise 
the midpoint potential of heme bL.   
For example, by using a FeS mutant with the lowest midpoint potential currently 
available in combination with substituting PQ for the native ubiquinone (UQ) at Qo, the 
normally unstable reactant state of reduced quinone and oxidized FeS and heme bL will 
become thermodynamically stable and experimentally accessible at the lowest pH values 
sustainable by Complex III (forest green section of Figure 6.2). Substituting the native 
UQ in the Qo site with the higher potential BQ creates this same redox state, and it is 
	  	  
Figure 6.2:  Manipulation of the midpoint potentials of cytochrome bc1 cofactors 
allows us to create, at equilibrium, two different intermediate states of the Qo site.  
The darker green regions of the graph represent the midpoint potential and pH 
combinations that would promote a reduced quinone redox state, where Qo is poised 
to transfer electrons to FeS and heme bL.  Shown in light green is the fully oxidized Qo 
redox state, where FeS and heme bL are both fully reduced. Reprinted with permission 
from SpringerLink and the Journal of Bioenergetics and Biomembranes [2].	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more thermodynamically stable over a much wider pH range (lime green area of Figure 
6.2).  Stabilizing the other catalytically active state, where Qo is oxidized and both FeS 
and heme bL are reduced, requires the opposite strategy (light green of Figure 6.2).  
Attaining thermodynamic stability for this state requires replacing the native UQ with 
quinones that have intrinsically lower midpoint potential values, such as MQ, and raising 
the pH; mutants that raise heme bL midpoint potential can assist the formation of this 
redox state.  
While mutational changes to FeS midpoint potential have created a wide 
thermodynamic range for exploration [15-18], as shown in Figure 6.3, a similar 
adjustment of the midpoint of heme bL has proven more challenging [19-21].  There may 
	  
Figure 6.3:  The range of midpoint potentials of FeS that are available via 
characterized mutants are illustrated in brown.  So far, heme bL mutations show a more 
limited range of midpoint potentials, as shown in blue.   Also shown here are the 
midpoint potentials for several quinone molecules, including ubiquinone (UQ), 
menaquinone (MQ), plastoquinone (PQ), rhodoquinone (RQ), benzoquinone (BQ), 
and methanophenazine (MP).  As demonstrated in purple, depending on the split of 
the two electron transfer couples for the quinone, the maximum amount of 
semiquinone generated on an equilibrium timescale will vary. Reprinted with 
permission from SpringerLink and the Journal of Bioenergetics and Biomembranes 
[2]. 	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be some hope from preliminary electrostatic calculations that suggest glutamate and 
arginine residues outside of the PEWY loop could potentally lower heme bL midpoint 
potential [22].   
Once equilibrium is attained, these two states can be followed by traditional EPR 
or FTIR approaches, since they would no longer be constrained by a quasi-equilibrium 
timescale.  However, the most important use of this stabilization strategy may be the 
potential accessibility of these new equilibria to X-ray crystallography techniques.  One 
explanation for the absence of bound quinone in the Qo site is that quinone is only bound 
in the unstable, catalytically active states [13, 14], a hypothesis that could be confirmed 
once these states have been stabilized. 
While low midpoint potential FeS mutants are potentially useful in stabilizing the 
physiologically active oxidized and reduced quinone catalytic states for leisurely study at 
equilibrium, high midpoint potential FeS mutants are potentially useful for facilitating the 
creation of pseudo-equilibrium Qo semiquinone states using the light activation method 
of Zhang et al [23].  Figure 6.3 shows that as the midpoint potential split between the 
oxidizing and reducing couple of the two quinone electron transfers gets larger, and the 
equilibrium concentration of semiquinone at Qo becomes extremely small, the quinone 
redox couples approach and eventually surpass the midpoint potential values of FeS and 
heme bL.  By using a mutant of FeS with the highest possible midpoint potential (and 
therefore, the greatest oxidizing power), it becomes easier to strip one electron off the 
reduced quinone at Qo and leave the other stranded on the semiquinone when the b-chain 
is fully reduced.  Similarly, the use of higher potential quinones instead of native UQ 
should also facilitate the quasi-equilibrium formation of semiquinone at Qo.  Instead of 
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the pH 9 conditions required for semiquinone formation with native UQ, high midpoint 
potential FeS mutants and/or quinone substitutes at lower pH values can be used to verify 
that the semiquinone formed is relevant to the Qo catalytic cycle, and also to detail its 
engineering in the physiological mechanism. 
6.3.2 Maquettes as enzymes – the potential for future designs. Shown in 
Figure 6.4 are the uncatalyzed and catalyzed rates for Complex III and the synthetic 
enzymes created by this work.  One of the goals of protein design is to be able to 
understand the engineering of natural proteins enough to design simple model systems 
that reproduce natural activity levels.  The protein design work contained within this 
thesis is the first example of maquette proteins capable of near-natural turnover rates.  
The success of the AP6 and HP7 (high potential) designs as Complex III-like enzymes 
	   	   	  	  
Figure 6.4:  Uncatalyzed and catalyzed rates for natural and synthetic quinol-
cytochrome c oxidoreductase proteins.  Black arrows for the catalyzed rates represent 
natural Complex III and green arrows depict maquettes.  The green uncatalyzed arrow 
represents direct electron transfer between quinol and cytochrome c.  The maquettes in 
this work are the first synthetic proteins to demonstrate activity within the range of 
natural metabolic enzymes.  	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opens the door for studying other aspects of Complex III turnover, including superoxide 
production.  Complex III and Complex I are both known to be the major sources of 
superoxide generation, which can generate acute cellular damage when recovering from 
temporary anoxia [24, 25].  It is also known that superoxide generation by Complex III is 
closely connected with disruption of mitochondrial membrane permeability, a key step in 
programmed apoptosis [26].  The superoxide anion midpoint potential has been estimated 
at –140 mV [27], so either heme bL or a SQ/Q couple at Qo are capable of supporting 
single electron reduction of oxygen.  Whether heme bL [14, 28, 29],  SQo [25] or both are 
the immediate donors to oxygen to make superoxide is unknown, and has been difficult 
to unravel in part because the mechanism at the Qo site remains unknown.  Also, another 
complication is the generation of the heme bL or SQ reducing states in an oxygen-rich 
environment is a state far from chemical equilibrium, and controlling the balance 
between reduced SQo or reduced heme bL has been an uncertain task.  Finally, 
superoxide generation has almost always been studied with multiple turnover systems of 
Complex III, where the redox states of all the Complex III components are rapidly 
changing and interrelated, offering little hope of discriminating between the redox states 
of heme bL and SQo in a natural system.  Studying superoxide production by maquette 
proteins yields greater control over the protein system.  Instead of trying to unravel 
results from a complex chain of redox cofactors, specific cofactors can be incorporated 
into the AP6 maquette to isolate their superoxide production.   
Heme bL is likely to form an oxyferrous state.   This would point towards an inner 
sphere electron transfer mechanism for superoxide production at heme bL, where an oxy-
ferrous transition state exists prior to oxygen reduction and release of superoxide.  
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Determining the conditions for superoxide production by heme b would be feasible using 
AP6.  Figure 6.5 depicts how this reaction could take place in AP6. “Leaky” AP6 
assembly does allow oxygen to enter the protein core (Figure 3.9) and associate with a 
reduced heme cofactor, and should also enable inner sphere electron transfer to form 
superoxide.   
AP6 can also be modified to study superoxide production by a semiquinone state.  
It has been suggested that Qo mobility would be essential to regulating its role in the 
	  	  
Figure 6.5 Cartoon of inner sphere electron transfer between a reduced heme in AP6 
and oxygen to form the superoxide anion.  AP6 helices (shown in blue) have a 
dynamic assembly that permits small ligands, such as oxygen (shown in red), to access 
the heme binding site (depicted as green histidine imidizole groups in this diagram) 
and form an oxyferrous intermediate state that then reduces oxygen to superoxide.   	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generation of superoxide [30-32].  According to this hypothesis, SQo would reduce 
oxygen through an outer sphere electron transfer mechanism when the quinone is present 
in the Qo active site.  A quinone cofactor could be fixed in a position along the AP6 
helix, in the form of a napthoquinone amino acid, in order to study reactions that produce 
superoxide in a similar way to reactions that could occur at Qo.  However, experiments 
prolonging the semiquinone redox state in natural Complex III have been successful at 
determining whether or not SQo is capable of superoxide production [32], and should 
also be utilized for future studies. 
6.4 Conclusion 
 Assigning a Qo site mechanism remains an elusive goal despite the experimental 
progress made since Peter Mitchell’s Q-cycle proposal in 1976 [33, 34].  In order to 
differentiate between the mechanisms currently proposed, future studies need to push the 
boundaries of current Complex III experiments and generate redox states that are, at 
present, too short-lived to be studied spectroscopically.  If these states cannot be 
distinguished using natural systems, maquette protein designs that target these quinone 
transition states could be studied in order to accept or reject potential Qo mechanisms. 
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Appendix 
A.1 The Moser Dutton equation – a useful predicting tool 
 The Dutton laboratory has developed an electron transfer rate expression that 
offers a simple way to examine parameters that directly relate to the oxidoreductase 
activity of a particular mitochondrial enzyme [1-3].  The Moser-Dutton equation defines 
the rate of electron transfer as a function of distance (R), midpoint potential (included in 
ΔG°), reorganization energy (λ), and protein packing density (ρ): 
 
 
Equation A.1 
This equation is based upon an exponential dependence of electron tunneling with 
distance through an insulating protein barrier, where the height of the tunneling barrier 
depends upon how vacuum-like or how bond-like the intervening protein medium is.  An 
elementary structure-based estimate that roughly correlates with effective barrier height is 
the packing density, which is around 0.76 in a typical protein.  Marcus realized that 
electron tunneling often has a Gaussian dependence of rate vs. distance [4], with a 
maximal possible rate when the driving force (-ΔG° in eV) matches an energetic term 
called the reorganization energy for electron tunneling.  The reorganization energy can be 
thought of as the energy required to move the nuclei of the redox cofactors and their 
surroundings from an equilibrium configuration favored when the electron is on the 
donor to the equilibrium geometry favored when the electron is on the acceptor, but 
constraining the electron to remaining on the donor.   
! 
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 Marcus’s expression was based on a classical model in which the potential 
energy surfaces of the reactant (reduced donor and oxidized acceptor) and product 
(oxidized donor and reduced acceptor) were intersecting, parabolic, simple harmonic 
oscillator wells, with the reaction coordinate being a generalized one of nuclear 
vibration/reorganization that carried the reactant equilibrium geometry into the product 
equilibrium geometry.  In the Marcus classical view, the vibrations coupled to electron 
transfer are all of low enough energy that a non-quantized harmonic oscillator description 
is sufficient.  Previous studies with photosynthetic reaction centers over a wide range of 
cyrogenic temperatures have demonstrated that the Marcus expression is not as 
appropriate as an expression that uses vibrations coupled to electron transfer that have an 
energy higher than Boltzmann κT at room temperature [5].  The weighted characteristic 
frequency of vibration coupled to electron transfer in reaction centers appears to be close 
to 0.06 eV, larger than the Boltzmann room temperature energy of about 0.025 eV [6].  
Hopfield has previously described an expression that allows this quantized vibrational 
frequency but maintains a Gaussian free energy dependence on rate [7].  Although this 
characteristic frequency is rather difficult to access experimentally and may vary from 
one electron tunneling reaction to another, the generic value appears to give reasonable 
estimates of electron transfer rates in many cases.  The somewhat broader quantized 
version of the Gaussian dependence of rate on free energy gives rise to the 3.1 coefficient 
in the room temperature expression of Equation A.1.  The corresponding classical Marcus 
expression would have a coefficient of 4.2. 
 Equation A.1 relates to exergonic electron transfer reactions; however, many 
biological electron tunneling reactions are uphill.  One way to estimate the rate of an 
	   136	  
uphill electron tunneling reaction is to use Equation A.1 to calculate the corresponding 
downhill electron transfer of the reverse reaction and then, assuming the forward and 
reverse rates are related by a Boltzmann energy term, slow the forward tunneling rate by 
an order of magnitude for every 0.06 eV of uphill free energy [3]. 
 Tunneling expressions with fewer parameters are useful in situations where there 
is a lack of experimental information.  Packing density is the easiest parameter to replace 
with a generic value because it rarely has a dominant effect (see Appendix for an 
example of this).  The 0.76 packing density typical of a protein leads to the 0.6 
coefficient leading the distance term.  The next parameter to consider replacing with a 
generic term is reorganization energy, both because it is rarely measured with any 
precision, and because it does not appear to be engineered in Complex III.  0.7 eV is an 
adequate generic value, and leads to a two-parameter expression: 
 
 
Equation A.2  
 In order to calculate the electron tunneling rates, user-written programs were 
constructed in Mathematica 7.0 (Wolfram Research).   
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